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ABSTRACT 
I discovered that certain electrophilic prostaglandins inhibit the ubiquitin-
specific protease (USP) activity of the proteasome pathway. Herein, evidence is 
presented that supports the hypothesis that the cross-conjugated a,~-unsaturated 
dienone is a molecular determinant for the potency of this activity, and that this 
chemical feature causes an alteration in cellular ubiquitin dynamics, resulting in 
decreased free ubiquitin and decreased protein degradation. I show that this 
decrease in protein degradation activates the unfolded-protein response (UPR) of 
both thf! cytoplasm and the endoplasmic reticulum, likely due to the accumulation 
of deranged/rnisfolded proteins. I make the novel observation that as an attempt to 
compensate for the loss in protein degradation by the proteasome pathway, the 
lysosomal degradation pathway is activated in USP inhibitor treated cells. Lastly I 
show that, ultimately, cell death occurs due to the build-up of toxic levels of 
cellular protein. These data reconcile previously known effects of prostaglandin 
treatment, namely that heat-shock proteins are up-regulated and that a number of 
short-lived proteins are stabilized, and in so doing, establish a cohesive model for 
prostaglandin-induced apoptosis. The potential that components of the ubiquitin-
proteasome pathway may be useful targets for cancer chemotherapy has been 
realized only recently with the success, in human clinical trials, of the proteasome 
inhibitor, VELCADE™ (PS-341). Given that several hundred other potential 
molecular targets reside within the proteasome pathway, there is intense interest 
in discovering novel points for drug intervention. Our data suggest that inhibition 
of USP activity represents a legitimate target for chemotherapeutic development. 
v 
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CHAPTER 1 
INTRODUCTION: UBIQUITIN-PROTEASOME PATHWAY IN CANCER 
1.1. Overview of Ubiguitin-Proteasome Pathway 
The ubiquitin-proteasome pathway is responsible for the degradation of 70 
to 90 percent of all cellular proteins 1. As the principal means for cellular protein 
degradation, this pathway has two primary functions: a regulatory function (i.e., 
the targeted degradation of functionally competent proteins) and a quality control 
function (i.e., the degradation of misfolded, functionally incompetent proteins to 
prevent protein aggregation) 2.3. Underscoring its importance to cellular 
homeostasis, the ubiquitin-proteasome pathway is present in all eukaryotes and 
many of its components are highly conserved 4. Owing to the recent clinical 
success of the proteasome inhibitor, VELCADE™ (PS-341), the components of 
this pathway have generated a great deal of interest as targets for cancer 
chemotherapy. The focus of this chapter is to describe, in some detail, the 
components of the ubiquitin-proteasome pathway, the major processes controlled 
by this pathway, known derangements in the pathway that may lead to 
carcinogenesis, how inhibitors of this pathway may cause preferential cancer cell 
death, and preliminary results from the clinical trials of VELCADE™. 
1.1.1. Ubiquitin-Proteasome Pathway Components 
The ubiquitin-proteasome pathway (Figure 1.1) is comprised of four major 
elements: a protein that serves as a signal for the degradation of targeted proteins, 
enzymes that covalently attach that signal to the targeted proteins, the proteolytic 
complex that degrades the targeted proteins while sparing the signaling protein, 
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Figure 1.1. The Ubiguitin-Proteasome Pathway. Schematic depicts the 
ubiquitination and degradation of a targeted protein by the ubiquitin-proteasome 
pathway. The cyclic nature of the pathway is derived from the perspective of 
ubiquitin. 
3 
may be used in another round of targeting. Together, these elements form the 
basis for the primary means by which all eukaryotic cells degrade intracellular 
proteins 1. The proteasome also plays an important role in antigen presentation, 
though this aspect will not be addressed in this work. 
1.1.1.1. Ubiquitin 
4 
The protein that can serve as a signal for proteasome-mediated 
degradation is ubiquitin. Ubiquitin is present in all eukaryotes, and is expressed in 
every cell type that has been examined, at concentrations approaching 1 llM. It is 
comprised of 76 amino acids, the sequence of which is highly conserved from 
yeast to humans (96 percent identity in primary structure), making it one of the 
most highly conserved eukaryotic proteins known 5. Three classes of genes have 
been identified that, when expressed, produce ubiquitin; all of the ubiquitin gene 
products result in ubiquitin fusion proteins, in which the carboxyl-terminus of 
ubiquitin is fused to the amino-terminus of another protein, and therefore must be 
post-translationally processed to release monoubiquitin 6,7. The translational 
products of the two UBA genes are single ubiquitin units fused to the amino-
termini of the small ribosomal proteins, s27a and L40; this fusion is believed to 
aid in the proper folding of the ribosomal proteins 8. The translational products 
UBB and UBC genes are fused multimers of ubiquitin, with the UBB gene 
consisting of three ubiquitin units and the UBC genes consisting of up to seven 
ubiquitin units 6. 
In a process that will be described below, either a ubiquitin monomer 
(monoubiquitination) or a ubiquitin polymer (polyubiquitination) can be 
covalently bound to a targeted protein (Figure 1.2). Unlike the peptide bond-
linked ubiquitin fusion proteins that are the products of the ubiquitin genes, 
monoubiquitination results in the formation of an isopeptide bond 9. The 
isopeptide bond is a covalent bond between the carboxyl-terminus of ubiquitin 
and the £-amino group of a lysine on the targeted protein. In the case of 
polyubiquitination, a targeted protein substrate is first monoubiquitinated on a 
lysine residue via an isopeptide bond. Then, ubiquitin monomers are added 
sequentially, via isopeptide bonds, to lysine residues on the preceding ubiquitin. 
Alternatively, preassembled polyubiquitin can be conjugated to targeted proteins 
1O.1l. The end of the polyubiquitin chain that is attached to the target substrate is 
termed the proximal end. 
1.1.1.2. Ubiquitin Activating, Conjugating, and Ligating Enzymes 
5 
Three enzyme families playa part in the ubiquitination of targeted 
proteins: El ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes (or 
ubiquitin-carrier enzyme), and E3 ubiquitin-ligating enzymes 12. There are only a 
few known El enzymes, approximately 50 E2 enzymes, and as many as 1000 E3 
enzymes. El ubiquitin-activating enzymes function, in an ATP-dependent 
manner, to form a high-energy thioester bond between the carboxyl-terminus of 
ubiquitin and a cysteine sulfhydryl group in the El active site 13. This high-energy 
bond is used to transfer ubiquitin to E2 ubiquitin-conjugating enzymes, 
Figure 1.2. The Isopeptide Bond. Schematic depicts the monoubiquitination and 
polyubiquitination of a targeted substrate. Chemical structures show the lysine 
side chains for a targeted substrate (monoubiquitination) and for ubiquitin 
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which functions as a carrier protein and works in concert with the E3 ligases 12. 
Depending on the type of E3 ligase involved (HECT, RING finger. PhD, or U-
box domain ligases), the ubiquitin bound to the ubiquitin-conjugating enzyme 
can either be directly conjugated to the targeted protein (RING finger ligases), or 
first transferred to an E3 ligase (HECT domain ligases), which via another 
thioester bond, conjugates ubiquitin to the targeted protein 14.15. Of these three 
major enzyme families involved in ubiquitination, it is the E3 ligases that appear 
to confer substrate specificity to the ubiquitin-dependent pathways. 
Although much remains to be discovered about the properties conferred by 
monoubiquitination, several effects have been demonstrated. As has been shown 
with the ubiquitin interacting motifs (UIMs) of the endocytic proteins. Eps 15 and 
eps 15R, monoubiquitination can result in changes in protein-protein interactions 
by serving as a removable targeting domain 16. Also, monoubiquitination can 
result in endocytosis and lysosomal degradation of membrane bound proteins. 
such as epidermal growth factor receptor (EGFR) 17. Lastly, as will be discussed 
in more detail in section 1.1.2.3., monoubiquitination of histones in yeast has 
f f' ., 18 elects on gene tranSCrIptIon . 
Like monoubiquitination, much remains to be discovered about the varied 
effects conferred by polyubiquitination of targeted proteins. However, the primary 
reason for these varied effects is related to the way in which the isopeptide 
linkages in the polyubiquitin chain are assembled. There are multiple lysines on 
ubiquitin that can be utilized to form polyubiquitin chains, lysine 11 (KIl), K29, 
K48, and K63 19, 
K48-linked polyubiquitin chains, the best characterized of the chain 
linkages, target proteins for proteasomal degradation by serving as a recognition 
signal by the 26S proteasome 20. In order for a protein to be targeted for 
proteasomal degradation, a polyubiquitin chain consisting of four or more K48-
linked ubiquitin subunits must be attached 21. As mentioned, this can be 
accomplished by covalent modification with a preassembled polyubiquitin chain 
or by the sequential addition of ubiquitin monomers. 
9 
Unlike the K48-linked chain, the K63-linked polyubiquitin chain does not 
appear to target proteins for proteasome-mediated degradation. As has been 
suggested with K63-linked polyubiquitination of proliferating cell nuclear antigen 
(PCNA), in some cases this modification may serve as a signal or framework for 
the assembly of enzymatic complexes (see section 1.1.2.4.) 22. The ubiquitin 
ligase, Traf6, catalyzes the formation of K63-linked chains. Conjugation of K63-
linked chains by Traf6 has been shown to activate protein kinases of the NFKB 
pathway, TAKI and IKB kinase (lKK), and the lun N-terminal kinase pathway, 
lNKlp38 23,24. Finally, K63-linked chains appear to play an essential role in the 
nonproteasomal degradation of membrane proteins such as Gap 1, whereby this 
type of polyubiquitin chain acts as a signal for endocytosis 25. 
Recent evidence has suggested a role for the Kll-linked polyubiquitin in 
regulating the localization of the chaperone recruiting protein, BAG-l 26. This 
BAG-l modification appears to be mediated by the heat-shock protein (HSP) 
associated ubiquitin ligase, CHIP, targeting CHIP to the proteasome. Remarkably, 
proteasomal targeting of CHIP does not target it for degradation. The function of 
CHIP on the proteasome appears to be related to the recruitment of HSPs, 
presumably so that they may deliver protein substrates for degradation 26. 
10 
No function has of yet been assigned to the K29 linkage, but the formation 
of this linkage has been observed in rabbit reticulocyte lysate as well as in yeast. 
suggesting it plays some physiological role 27.28. Therefore, there is still much to 
learn about all of the effects polyubiquitination can have on substrates. 
1.1.1.3. The 26S Proteasome 
The next component of the ubiquitin-proteasome pathway consists of the 
approximately two megadalton 26S proteasome, which is tasked with the 
degradation of polyubiquitinated substrate proteins 20. In vertebrates, the core of 
this complex is the 20S catalytic subunit, which is made up of four concentric 
rings: two identical adjacent inner rings, consisting of seven different B-subunits 
each, and two identical outer rings, consisting of seven different a-subunits each 
(Figure 1.3) 29. In addition, three y-interferon-inducible B-subunits can be 
expressed that substitute for the constitutively expressed B-subunits 30,31. The B-
subunits are threonine proteases that possess all of the proteolytic activity of the 
complex, however, in eukaryotes, only three of the seven subunits appear to be 
active 32. The outer a-subunits appear to serve two main functions: as a docking 
site for the 19S regulatory subunit, and as a regulatory mechanism that prevents 
the entry of substrates into the catalytic chamber in the absence of the 19S 










Figure 1.3. The Proteasome Components. Schematic depicts the 20S proteasome 
core, a cross-section of the core particle, and the 26S proteasome holoenzyme. 
11 
12 
The 19S regulatory subunit is made up of at least 18 proteins and 
functions as a recognition element for the polyubiquitin degradation signal. and as 
an ATP dependent protein-substrate unfolding complex 34. It is the 19S regulatory 
subunit that recognizes and binds polyubiquitinated substrates. The requirement 
for this binding is that the targeted substrates have a polyubiquitin chain of at least 
four ubiquitin units attached, and that the chain is of the K48-linkage type 21. 
These requirements, as well as the necessity of protein-substrate unfolding in 
order to access the catalytic chamber, are what prevent the proteasome from 
performing indiscriminant protein degradation. 
1.1.1.4. Ubiquitin-Specific Proteases (Ubiquitin Isopeptidases) 
The final family of enzymes in the ubiquitin-proteasome pathway is the 
ubiquitin-specific protease (USPs) family. These enzymes are also termed 
isopeptidases (the term used throughout this thesis). This family is comprised of 
as many as 90 members, most of which are cysteine proteases 35,36. They are 
broken down into three major types according to protein sequence homology: 
ubiquitin C-terminal hydrolases (UCHs), ubiquitin processing proteases (UBPs), 
and a newly identified class, the metalloproteases 37. 
Isopeptidases have in common the ability to hydrolyze peptide or 
isopeptide bonds between the C-terminus of ubiquitin and another protein (Figure 
1.4). Therefore, the various members of this enzymatic class can process ubiquitin 
fusion proteins (products of the ubiquitin genes), remove small peptide remnants 
present on the proximal end of polyubiquitin following proteasomal degradation, 
13 
Figure 1.4. Isopeptidase Substrates. Schematic depicts the isopeptidase-mediated 
hydrolysis of a linear ubiquitin fusion protein (peptide bond hydrolysis) and a 
monoubiquitinated protein (isopeptide bond hydrolysis). 
14 
Hydrolysis of ubiguitin fusion proteins 
! Isopeptida.-se_ 
Hydrolysis of isopeptide bonds 
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Ub Ubiquitin 
s27a Ribosomal protein s27a 
edit improperly polyubiquitinated protein substrates, and rescue targeted protein 
substrates from proteasomal degradation 35. 
15 
The UCHs are the smallest of the isopeptidase family, with molecular 
weights of less than -40 kilodaltons. UCHs contain Cys and His boxes. 
characteristic secondary structure elements of the cysteine protease class of 
isopeptidases that make up the catalytic core of these enzymes 38. As is common 
with the isopeptidase family, the regulation, tissue-specific expression. and 
substrate specificity of the UCHs is largely unknown. Of this class. only the 
brain-specific UCH-Ll (Protein Gene Product 9.5, PGP 9.5) has been 
characterized as having tissue specific expression 39. Interestingly, this 
isopeptidase is overexpressed in a number of cancers and cancer cell lines, though 
its role in this regard has not been elucidated 40AI. The only UCH having a 
proposed function is UCH-L5, a 19S regulatory cap isopeptidase that appears to 
play an essential role in proteasomal degradation 42. 
The UBPs are the largest of the catalytic cysteine-containing ubiquitin 
protease class, having molecular weights ranging from 50 to 250 kilodaltons. 
UBPs share in common with the UCHs the Cys and His boxes, however the 
remainder of the sequences of these two classes are largely divergent, as they 
most likely playa role in regulation or substrate recognition of the individual 
isopeptidases 35. Like the UCHs, little is known about the substrate specificity of 
the individual UBPs, with two exceptions; isopeptidase-T (USP5) appears to be 
primarily responsible for the disassembly of polyubiquitin, starting from the 
proximal end, and USP16 appears to deubiquitinate the monoubiquitinated 
histones, H2A and H2B 43.44. Given that ubiquitin is ligated to so many diverse 
substrates, the role of many of the remaining isopeptidases is likely to be in the 
regulation of ubiquitination of these proteins. In addition, some of these 
isopeptidases may playa role in the removal of some of the approximately II 
ubiquitin-like proteins (e.g., Nedd8, Sumol, etc.) 45. 
The most recently identified family of ubiquitin specific proteases is the 
metalloprotease family. During ubiquitin-mediated proteasomal degradation. the 
polyubiquitin degradation signal is spared the fate of the targeted protein via the 
actions of isopeptidases resident in the 19S regulatory subunit, which release 
polyubiquitin from the complex. One of these isopeptidases has recently been 
identified as the zinc protease, POH I 37. It shares no protein sequence homology 
to the known cysteine protease isopeptidases; however it has significant 
homology to JAB I, a protein known as an isopeptidase for the ubiquitin-like 
protein, Nedd8 46. 
1.1.2. Substrates of the Ubiquitin-Proteasome Pathway and 
Cellular Processes Controlled 
16 
As mentioned, the proteasome is responsible for the degradation of 70 to 
90 percent of proteins in the cell. It is therefore easy to understand that the 
proteasome pathway in some way modulates most cellular processes (e.g., cell 
cycle regulation, apoptosis, and transcription, etc.). The importance in 
understanding the implications of modulation of these processes becomes evident 
when considering both the diseases that arise from aberrant proteasomal 
degradation as well as the therapeutic manipulation of the ubiquitin-proteasome 
pathway. 
1.1.2.1. The Cell Cycle 
17 
Cyclin-dependent kinases (CDKs) are the primary effector molecules that 
regulate the cell cycle 47. CDKs are constitutively expressed throughout the cell 
cycle, so their activity must be modulated in order for proper cell cycle balance to 
be maintained. This activity is modulated via association with two classes of 
regulatory molecules: cyclins (e.g., cyclins A, B, D, and E) and cyclin-dependent 
kinase inhibitors (CDKIs; e.g., p21 Cipl and p27Kipl ) 47,48. Cyclin binding activates 
CDKs while CDKI binding inhibits activation of CDKs. It is the fluctuations in 
cyclin and CDKI protein levels that modulate CDKs, and therefore the cell cycle. 
Two large complexes playa dominant role in regulating cyclin and CKDI 
protein levels; the SCF ubiquitin ligase complex, so called because it is composed 
of the Skpl, Cullin, and F-box proteins, and the anaphase-promoting complex 
(APC), which is composed of a Cullin homolog and several other proteins 
unrelated to those of the SCF complex 49. The F-box proteins of the SCF complex 
are variable subunits that allow for the targeting of diverse substrates for 
ubiquitination 50. The APC complex is believed to have variable targeting 
subunits similar to F-box proteins. The APC complex targets cyclins A and B for 
ubiquitination, while the SCF complex targets cyclin E and the CDKI, p27 49, 
Although the regulation of this process is considerably more complex than 
discussed here, clearly the ubiquitin-proteasome pathway plays a major role in 
cell cycle regulation. 
1.1.2.2. Apoptosis 
Analogous to the balance maintained with the components of the cell 
18 
cycle machinery, the proteasome pathway is also essential in maintaining control 
of the balance between life and death of the cell. As this balance is tilted toward 
programmed cell death, or apoptosis, events lead to the activation of the effector 
molecules of cell death, caspases 51, Caspases reside in cells in a pro-apoptotic 
form, awaiting signals leading to their cleavage and activation, which in turn leads 
to the cleavage and activation of other caspases in a cascade resulting in cell 
death. In order to prevent premature initiation of caspase cascades. inhibitor of 
apoptosis proteins (lAPs) bind to activated caspases, preventing their ability to 
initiate the cell death cascade 52, 
Some lAPs (e.g. XlAP, c-lAPl, and c-lAP2) are E3 ubiquitin ligases, the 
significance of which is not yet completely understood 52. However, one 
identified function of this E3 ligase activity is for lAP autoubiquitination 53. In 
fact, experiments have shown that wild type E3 ligase lAP protein levels decrease 
during apoptosis, while generated mutant lAPs lacking the ring finger motif 
essential for ubiquitination are relatively stable and prevent apoptosis 53. This 
suggests that autoubiquitination of lAPs is activated upon induction of apoptosis, 




Transcription factors are important regulators of processes as di verse as 
cellular homeostasis, differentiation, and oncogenic transformation. Many tumor 
suppressors are transcription factors whose cellular protein levels, and therefore 
activity, are regulated by proteasomal degradation 54. The p53 tumor suppressor is 
one such transcription factor, the intracellular levels of which are kept low, under 
basal conditions, by the actions of the E3 ubiquitin ligase, human double-minute 2 
(HDM2) 55,56. Upon sensing genomic damage, or other indicators of cellular 
stress, posttranslational modifications to both p53 and HDM2 prevent their 
association, and p53 ubiquitination, allowing for the intracellular accumulation of 
p53 so that it may act as a sentinel of genomic integrity 57, 
Nuclear factor kB (NFKB) is a transcription factor whose activity is 
regulated indirectly by proteasomal degradation. Under basal conditions NFKB is 
inhibited by its association with the protein, inhibitor of KB (IKB) 58. IKB 
functions as an inhibitor of NFKB by binding to, and thus masking, the NFKB 
nuclear localization signal. Upon activation of cell surface receptors, a chain of 
events unfolds, leading to the activation of the serinelthreonine kinase, IKB kinase 
(IKK), which phosphorylates IKB, causing it to dissociate from NFKB and be 
targeted for proteasomal degradation 58. This action exposes the NFKB nuclear 
localization signal, allowing for nuclear import of NFKB and activation of NFKB 
target genes. 
The ubiquitin-proteasome pathway also regulates transcription via 
ubiquitination of the transcriptional activation domain (TAD) present on many 
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transcription factors 59. Interestingly, the TAD domain serves not only as an 
activator of transcription, but also as the proteasome-mediated degradation signal, 
or degron, of these transcription factors. As such, the TAD domain requires 
ubiquitination for both its activation and degradation. Like other substrates for 
ubiquitination, TAD domains appear to be selectively ubiquitinated, thus allowing 
for the discreet regulation of individual transcription factors and subsequent target 
gene families. 
Finally, ubiquitination can regulate transcription in a more general way, 
via ubiquitination of his tones us. Histones are proteins that serve as a 
structural/regulatory core around which DNA is wrapped to form chromatin 60. 
Histones are the most abundant ubiquitinated cellular proteins and were once 
believed to merely serve as a pool of monoubiquitin that could be tapped during 
times of cellular stress. However, ubiquitin already exists in the cell as a large 
pool of monoubiquitin, leading others to hypothesize that a more significant role 
for histone monoubiquitination may involve DNA function. 
The current model for DNA transcription suggests that basic lysine 
residues on the N-termini of histones cause DNA to tightly bind these molecules, 
thereby leading to gene repression 61. Neutralization of the positive charge on one 
or more of these lysines, via acetylation or methylation, results in the local 
unwinding of the histone-DNA complexes, allowing for local gene transcription. 
Recent evidence in yeast has demonstrated that methy lation of histone H3 (on K4) 
is necessitated by the monoubiquitination of histone H2B (on K 123) by the 
ubiquitin conjugating enzyme, Rad6, thereby providing a mechanistic link 
between ubiquitination and gene transcription 18.62. 
1.1.2.4. DNA Repair 
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Another role of the ubiquitin-proteasome pathway that has been recently 
discovered is that of DNA repair 22. Proliferating cell nuclear antigen (peNA) is a 
protein known to be involved in DNA synthesis and repair 63. Work in yeast has 
demonstrated how ubiquitin plays a role in error-free DNA repair. This type of 
repair, dependent on DNA replication, uses the undamaged sister duplex as a 
template to replace a damaged base 64.65. When error-free DNA repair is not 
available, error-prone DNA repair takes place by default, using translesion 
polymerases to replace the damaged base with any of the four bases 66. The latter 
repair method can obviously result in DNA mutations leading to the production of 
aberrant proteins. The model generated by this recent work in yeast suggests that 
the Rad6 ubiquitin-conjugating enzyme associates with the Rad 18 ubiquitin 
ligase, resulting in monoubiquitination of peN A 22. Rad6/Rad 18 can then form a 
larger complex with the Ubc 13 ubiquitin conjugating enzyme and the Rad5 
ubiquitin ligase to form a lysine-63 linked polyubiquitin chain on the previously 
ligated ubiquitin. As mentioned previously, the K63 linkage in polyubiquitin does 
not generally lead to degradation, as does K48-linked polyubiquitin. As 
anticipated, mutation of the ubiquitinated lysine (K164R) of peNA led to 
sensitivity to DNA damaging agents 22, 
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Yeast PCNA shares 35 percent identity in its primary structure with 
human PCNA, and importantly, lysine 164 is conserved 63. Ubiquitinated PCNA 
was not observed in untreated HeLa cells. However, when these cells were treated 
with a DNA damaging agent, polyubiquitinated PCNA was observed 22. If this 
polyubiquitinated PCNA is K63-linked, this will demonstrate the first link in 
humans between ubiquitination and DNA repair processes. 
1.2. Derangements in Proteasomal Degradation That Are 
Implicated in Carcinogenesis 
Given that the ubiquitin-proteasome pathway plays such a prominent role 
in cellular protein degradation, and that the activity of many proteins is 
proportional to their intracellular concentration, it is not surprising that many 
diseases can arise due to the aberrant degradation of particular substrates, 
Accordingly, alterations in proteasomal degradation have been linked to 
carcinogenesis. Discussed in this section are just a few of the many examples of 
dysregulated proteins and the proposed mechanisms regarding their role in 
carcinogenesis. 
1.2.1. Human Papillomavirus E6 Oncoprotein 
Approximately 200,000 women die worldwide from cervical cancer every 
year. Most cases of cervical cancer have been associated with the presence of the 
human papillomavirus E6 (HPV-E6) oncoprotein 67, This oncoprotein forms a 
complex in cells with an endogenous host protein, E6-associated protein (E6-AP), 
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Analogous to the endogenous p53-specific E3 ubiquitin ligase, HDM2, the HPV-
E61E6-AP complex functions as an E3 ubiquitin ligase for the p53 tumor 
suppressor, resulting in decreased basal levels of p53 protein 68. However, unlike 
HDM2, the E6 oncoprotein is not itself regulated upon cellular exposure to DNA 
damage or cellular stress, therefore it continues to act in conjunction with E6-AP 
to prevent the accumulation of p53, resulting in decreased genetic surveillance. It 
is believed that this chronic suppression of p53 leads to the accumulation of 
secondary genetic mutations, some of which may eventually lead to cancer 
progressi on. 
1.2.2. NFKB Pathway 
The increase in tumor burden that is the phenotypic hallmark of cancer is 
most often the result of increased cellular proliferation. However, a phenomenon 
that can have equally important implications, both in terms of cancer mechanism 
and in terms of how a particular cancer can be most successfully treated, is 
decreased cell death. As discussed above, NFKB is a transcription factor that is 
indirectly regulated by the ubiquitin-proteasome pathway. The expression of 
genes that are regulated by NFKB, such as lAPs (section 1.1.2.2.). can result in 
increased cell survival 69.70. Also, NFKB activation can induce the expression of 
anti-apoptotic Bel2 family members, resulting in increased resistance to 
chemotherapeutic agents 71. Furthermore, overexpression of either IKK or NFKB 
is sufficient to result in the transformation of cancer cells 72,73. Although no 
definitive mutations have been identified linking aberrant ubiquitination of its 
inhibitor, IKB, with carcinogenesis, increased levels of NFKB and its acti vator. 
IKK, have been observed in cancer cell lines 74, 
1.2.3. ~-Catenin 
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~-Catenin has two primary functions in cells; as an adherens junction 
protein, it plays a role in cell adhesion, and as a binding partner of T cell factor 
(Tcf) and lymphoid enhancer factor (Lef) transcription factors, it facilitates 
transcription of Wnt signaling pathway genes 75. Up-regulated ~-catenin has been 
linked to the pre-cancerous syndrome, familial adenomatous polyposis of the 
colon (FAP) 76, The primary genetic defect in this syndrome resides within the 
APe gene, the product of which (APC) interacts with and down-regulates ~­
catenin, and thus Wnt signaling 77, APC down-regulates ~-catenin by acting as a 
co-factor, with the serine-threonine kinase GSK-3~, in the phosphorylation of ~­
catenin 78, This phosphorylation allows for the recognition of f3-catenin by the F-
box protein, ~-TRCP, which in tum recruits f3-catenin to the SCF ubiquitin ligase 
complex so that it may be ubiquitinated and degraded 79, When either APC is 
deleted or mutated, or f3-catenin itself is mutated at its GSK-3f3 phosphorylation 
sites, either of which results in p-catenin accumulation and increased Wnt 
pathway signaling 80. 
1.2.4. Von Hippel-Lindau Syndrome 
Sensing of low oxygen by cells (hypoxia) prompts them to release signals, 
such as vascular endothelial growth factor (VEGF), that promote the growth of 
blood vessels 81. This signaling is mediated by the heterodimeric transcription 
factor l hypoxia-inducible factor (HIF). Under norrnoxic condition, N-terrninal 
proline residues of one of the members of this heterodimer, HIFa, become 
hydroxylated 82. Proline hydroxylation results in HI Fa being recognized by an F-
box protein, p VHL, and recruited to an SCF-like ubiquitin-ligase complex for 
proteasomal targeting 83. Under hypoxic conditions, proline hydroxylation does 
not occur, thus allowing HIF to transcribe its target genes. p VHL is mutated in 
Von Hippel-Lindau syndrome (VHL), a cancer susceptibility syndrome 
characterized by the presence of hemangioblastomas, or blood vessel tumors of 
the CNS 84. Thus, disease causing pVHL mutations prevent the recruitment and 
proteasonlal degradation of HIFa, allowing for constitutive activation of HIF 
genes, which account for the hemangioblastoma phenotype due to constant VEGF 
production. 
1.2.5. Cyc1in E 
hCdc4 is an F-box protein that targets cyc1in E for degradation via the 
actions of the SCF ubiquitin ligase complex 85. Cyclin E is expressed near the 
GOIG 1 to S-phase transition, functioning as an activator of cyc1in-dependent 
kinase 2 (Cdk2), which in tum facilitates the phase transition 86, Therefore 
targeted degradation of cyc1in E by the SCFhCdc4 complex is essential for 
preventing the aberrant transition to the S-phase in times of cellular crisis. 
The elevation of cyc1in E protein levels has been observed in a number of 
cancers, and appears due, in part, to the dysregulation of its degradation after the 
transition to S-phase 87. Mutations in hCdc4 have recently been identified in 
endometrial cancers as well as in a breast cancer cell line, both of which have 
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dysregulated cyclin Underscoring the importance of this discovery, the hCdc4 
gene resides in a region of a chromosome (4q32) that is deleted in over 30% of all 
human cancers 85.88. 
1.3. Hypotheses for Proteasome Inhibitors' Therapeutic Index 
It may not be readily apparent why the ubiquitin-proteasome pathway is a 
reasonable target for chemotherapeutic intervention. After all, every single cell 
has, and indeed relies heavily on, this pathway for cellular homeostasis. Below, 
we discuss several hypotheses as to why the proteasome pathway is a legitimate 
drug target for chemotherapy that will offer an acceptable therapeutic index. 
1.3.1. Up-regulated Proteasome Components in Cancer 
The proteasome pathway is hyperactivated in renal cell carcinomas, as 
compared to adjacent normal tissue, suggesting overall increases in protein 
degradation and increased cellular metabolism IN. Furthermore, other groups have 
demonstrated increases in the expression of ubiquitin fusion proteins 90,91. Just 
whether and how these alterations in proteasome function affect the pathogenicity 
of a particular cancer is an area of active investigation. However, even if the up-
regulation of the proteasome pathway is simply an effect of cellular 
transformation, it suggests that, at least in some cases, the increase in activity 
plays an important role in the viability of these cancers. 
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1.3.2. Inhibition of Specific Proteasomal Substrate Degradation 
As detailed above, several cancers have been linked to the aberrant 
degradation of particular proteasomal substrates. For example, the cyclin 
dependent kinase inhibitor, p27kipl , has been studied extensively and is found to 
be down-regulated in many cancers, including breast, colon, and prostate 92,93. If 
altered degradation of any substrates like p27 kipl leads to oncogenic 
transformation, then inhibition of the proteasome pathway in these cases may 
have significantly greater effects on the cancer cells versus normal cells. 
1.3.3, Converging Pathways 
Maintaining control of cell growth is extremely important to the survival 
of multicellular organisms. Therefore. it is understandable that redundancy exists 
in the function of the n10lecules that control cellular proliferation, tumor 
suppressors. It is not surprising then, that the preponderance of evidence suggests 
that multiple genetic alterations in tumor suppressor pathways are necessary for 
oncogenic transformation 94. As tumor cells undergo clonal expansion, they 
become increasingly genetically unstable, allowing for the accumulation of n10re 
mutations, in effect creating a population of cells related to, but characteristically 
different from, the progenitor cell 95.96. This often leads to sub-populations of cells 
that can become resistant to chemotherapeutic regimens. One hypothesis 
explaining why proteasome inhibitors might be clinically successful is that, 
because of the critical role of the proteasome pathway in virtually all cellular 
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processes, few genetically variant cells can escape death, increasing the likelihood 
that these agents will be equally effective against all sUbpopulations. 
1.3.4. Greater Sensitivity of Proliferating Cells to Proteasome Inhibitors 
Often, chemotherapeutic strategies (e.g., DNA damaging agents) are said 
to have acceptable therapeutic indices due to the fact that cancer cells are rapidly 
proliferating, encountering cell-cycle checkpoints more frequently, and therefore 
need the inhibited processes more than nonproliferating cells. This theory is 
certainly reinforced when one considers the side-effects of such chemotherapeutic 
regimens: toxicity to rapidly proliferating cells such as gastrointestinal cells, hair 
follicles, etc. 
In support of utilizing this hypothesis for proteasome inhibitors, several 
groups have demonstrated that proliferating cells undergo apoptosis when treated 
with proteasome inhibitors 97, Proteasome inhibitors do not appear to be as 
effective at inducing apoptosis in quiescent cells 98. Furthermore, the use of 
proteasome inhibitors in il1 vivo models has demonstrated significant reductions in 
tumor mass while remaining well tolerated by the model organisms, again 
suggesting sparing of quiescent cells 99, 
A paradox is encountered, however, when one considers that proteasome 
inhibitors are effective against B-celllymphomas, characteristically slow growing 
cancer cells 100, Therefore, another characteristic of cancer cells that may be 
playing an important role in cellular sensitivity to chemotherapeutic agents, like 
proteasome inhibitors, is cellular stability. Cancer cells may be inherently 
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unstable due to the conditions leading to their oncogenic transformation, and that 
perturbation in global processes, such as DNA synthesis, push the balance 
towards apoptosis. 
1.4. Proteasome Inhibitors as Antineoplastic Agents 
1.4.1. Proteasome Inhibitor Classes 
Prior to the work presented in this thesis, there was only one established 
mechanism of action by which the proteasome pathway could be inhibited in 
intact cells: inactivation of the 26S proteasome's catalytic activity. There are three 
classes of proteasome inhibitors most often used to study the proteasome 
pathway: natural products, peptide aldehydes, and peptide-mimic boronic acids 
(Figure 1.5). 
The natural product class consists of lactacystin and epoxomicin, and 
function by covalent reaction with the proteasome ~-subunits' catalytic threonines 
101,102. Lactacystin is an inactive Streptomyces metabolite that is converted to the 
active metabolite, clasto-Iactacystin ~-lactone, by spontaneous transesterification. 
The catalytic threonines of the proteasome react with the ~-lactone functional 
group irreversibly 101. Epoxomicin is an Actinomyces metabolite that reacts with 
the proteasome via its epoxide functional group 102. These inhibitors are less 
potent, but are more specific, than the peptide aldehydes. 
The peptide aldehydes work via a similar mechanism; they are peptide 
substrates containing electrophilic functional groups at their carboxyl-termini that 
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VELCADE™ (PS-341) 
Figure 1.5. Proteasome Inhibitor Classes. Shown are examples of natural product, 
peptide aldehyde, and peptide-mimic boronic acid proteasome inhibitors. These 
compounds all inhibit the catalytic sites of the proteasome. Prior to the work 
presented here, the only proteasome pathway inhibitors known were of these 
classes. 
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compounds are more stable and potent than lactacystin, but they tend to be less 
selective. The peptide aldehydes are also more readily accessible than lactacystin, 
due to their relatively low synthetic cost. 
The third class of proteasome inhibitors is the peptide-mimic boronic acids 
103, These transition-state analogs are both potent and selective, forming reversible 
adducts with the proteasome ~-subunit catalytic threonines. Of all of the 
proteasome inhibitors, only PS-341 is being pursued in cancer clinical trials. 
1.4.2. Preclinical and Clinical Evaluation of the Proteasome Inhibitor. 
PS-341 (VELCADE™) 
1.4.2.1. In Vitro Models of Human Disease 
Given the prominent role of the ubiquitin-proteasome pathway in cellular 
homeostasis, it is not surprising that disruption of this pathway with proteasome 
inhibitors is toxic to cells. Indeed, many studies have proven this to be true, 
prompting the discovery of novel, potent, and selective proteasome inhibitors. 
Such a compound, VELCADE™ (PS-34l), was discovered in a small molecule 
proteasome inhibitor library by ProScript, Inc. (now Millenium Pharmaceuticals, 
Inc.). PS-341 was chosen for development because it was found to be one of the 
most potent compounds from this library, in terms of causing cancer cell death 
and proteasome inhibition, and a high correlation exists between its cytotoxicity 
and proteasome inhibition (suggesting proteasome inhibition to be the primary 
mechanism of action) 104. Like peptide based inhibitors, PS-341 is active against a 
wide range of human cancer cell lines (e.g., colon, pancreatic, prostate, etc.) 105. 
32 
Because of the unique mechanism of action of proteasome inhibitors, another trait 
of PS-341 is that it retains activity against cell lines that are resistant to other 
chemotherapeutic agents 100. Furthermore, likely due to the role of the proteasome 
pathway in DNA repair, PS-34I has synergistic effects with a variety of DNA 
damaging agents (e.g., doxorubicin, CPT-II, and cisplatin) 106,107. Combined, 
these favorable properties prompted the continued examination of this compound 
in animal models. 
1.4.2.2. Animal Models of Human Disease 
As with model cell lines, in in vivo models, PS-34I has demonstrated a 
favorable profile. Most importantly, in mouse xenografts, this compound was 
found to reach its intended site of action and inhibit the catalytic activity of the 
proteasome in the implanted tumor 99,104. Furthermore, PS-341 appeared to be 
wel1 tolerated at concentrations that inhibit the proteasome substantially. As in 
cell studies, PS-341 is active in vivo against a wide range of human cancers (e.g., 
I , 1 1 I . d ) 99 108 I . . . . mu tIp e mye oma, co on, pancreatIc, an prostate ' . t retams activity agamst 
cell lines that are resistant to other chemotherapeutic agents, has synergistic 
effects with a variety of DNA damaging agents (e.g., 5-fluorouracil, cisplatin, 
Taxol and adriamycin), and demonstrates selective toxicity toward malignant cells 
109. The positive findings of these studies prompted the continued examination of 
this compound in human clinical trials. 
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1.4.2.3. Human Clinical Trials 
PS-341 has undergone Phase I clinical trials for solid tumors (43 patients. 
14 different diagnoses) and hematologic malignancies (27 patients, 8 diagnoses) 
110,111. As in animal models, PS-341 was well tolerated at concentrations in which 
it inhibited the proteasome. In the solid tumor trial, the major dose-limiting 
complications were diarrhea and sensory neuropathy (with two of the highest dose 
patients experiencing grade 3 of each). In the hematologic malignancy trial, the 
major dose-limiting complications were thrombocytopenia and anemia (with 10 
patients and 5 patients experiencing grade 3 or greater, respectively) Ill, Of 
course, when interpreting these dose-limiting toxicity data, one must consider that 
some of the complications encountered could be a reflection of treatments given 
prior to enrollment in these trials. 
As in the animal models, tolerated doses were sufficient to significantly 
inhibit the proteasome in tumor samples (approximately 65 percent proteasome 
inhibition for both trials), demonstrating that PS-341 was reaching its intended 
target in vivo. This activity slowly diminished to approximately 20 percent 
inhibition 3 hours after dosing (one bolus). 
Similar to what was observed in vitro and in animal models, PS-341 
appears to affect hematological malignancies to a greater extent than solid tumors. 
In the solid tumor trial, only 1 patient out of 43 showed a partial response Ill. 
However, in the hematological malignancy trial the results were more promising 
110, Of the 9 multiple myeloma patients that were available for follow-up, 5 
patients had a partial response, 3 patients showed disease stabilization, and one 
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patient has shown a full response, with no disease progression after 1 year. These 
results are remarkable when one considers that the patients in this trial had failed 
an average of four other standard therapies. This may be a reflection of what was 
observed in animal models; PS-341 can overcome cell resistance to standard 
therapies. 
Another disease category that shows promise for successful PS-341 
treatment is non-Hodgkin's lymphoma 110. Two of the 10 non-Hodgkin's 
lymphoma patients showed partial responses. One of these patients had failed 
prior treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone; 
autologous stem-cell transplantation; and radiation therapy. The second patient, 
who has a stable partial response after 12 months off therapy, failed prior 
treatment with cyclophosphamide, vincristine. prednisone, and rituximab. 
When evaluating these data, it must be taken into consideration that the 
two trials were designed slightly differently; the major difference being that in the 
solid tumor trial, one cycle represented PS-341 for 2 weeks followed by 1 week of 
no treatment, while in the hematological malignancy trial, one cycle represented 
PS-341 for 4 weeks followed by 2 weeks of no treatment. Therefore, a different 
treatment regimen may be more effective for solid tumors. Also phase II trials are 
being planned for PS-341 in combination therapies in the hope that this approach 
will be more amenable to treating solid tumors. 
Due to the promising results of the phase I trials, a phase II trial was 
initiated for approximately 200 mUltiple myeloma patients. This trial has recently 
been completed, however, the data for this study are not yet available. These 
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results were encouraging enough to enter a phase III multiple myeloma trial. This 
trial is currently underway with approximately 600 patients in 65 centers. 
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Electrophilic eicosanoids of tbe J series, witb tbeir 
distinctive cross-conjugated a,tl-unsaturated ketone, in-
activate genetically wild type tumor suppressor p53 in a 
manner analogous to prostaglandins of tbe A series. 
Like tbe prostaglandins of tbe A series, prostaglandins 
of the J series bave a structural determinant (endocyclic 
cyclopentenone) tbat confers the ability to impair the 
conformation, tbe phospborylation, and tbe transcrip-
tional activity of the p53 tumor suppressor with equiv-
alent potency and efficacy. However, J series prostag-
landins bave a unique structural determinant <exocyclic 
a,tl-unsaturated ketone) that confers unique efficacy as 
an apoptotic agonist. In seeking to understand how J 
series prostaglandins cause apoptosis despite their in-
activation of p53, we discovered tbat they inhibit tbe 
ubiquitin isopeptidase activity of the proteasome path-
way. In this regard, J series prostaglandins were more 
efficacious inhibitors than representatiVe members of 
the A, B, or E series prostaglandins. Disruption of the 
proteasome pathway with proteasome inhibitors can 
cause apoptosis independently of p53. Therefore, tbis 
finding belps reconcile the p53 transcriptional inde-
pendence of apoptosis caused by A12-prostaglandin J 2 • 
This discovery represents a novel mechanism for pro-
teasome patbway inhibition in intact cells. Further-
more, it identifies isopeptidases as novel targets for the 
development of antineoplastic agents. 
Certain electrophilic prostaglandins (PG)I can repress trans-
activation by NFKB and p53 (1-4), two prominent transcription 
factors that govern the decision of a cell to survive or die (5-7). 
This transcriptional repression is a pharmacologically unique 
trait that distinguishes PG of the A and J series from other PG 
that act via membrane-spanning receptors (8L If the endocyclic 
a,{3-unsaturated ketone shared by A and J series PG confers 
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Ida W, Smith Chair for Cancer Research, To whom correspondence 
should be addressed, Tel.: 801-581-6204; Fax: 801-585·0101; E·mail: 
frank, fi tzpatrick@hci,utah,edu, 
I The abbreviations used are: PG, prostaglandin(a); Ac-DEVD-MCA, 
acetyl-Asp-Glu-Val-Asp-methylcoumarin-7 -amide; 1KE, inhibltor of 
NFKB; NFKB, nuclear factor KB: z-LLE-MCA, carbobenzoxy-L-leucyl·L-
leucyl-L-glutamate a-(4-methyl-coumaryl-7-amide); z-LLL-MCA. carbo-
benzoxY·L-leucyl-L-leucyl-L-leucine Q.( 4- methy l-coumaryi -7 -am id e); 
LLVY·MCA, 8uccinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosme a-(4-methyl-
coumaryl· 7 -amide); z-LRGG-MCA. carbobenzoxY-L-leucyl-L-arginyl, l-
glycyl-l-glycine Q-(4-methyl-coumaryl-7-amide); MG1l5, carbobenzyloxy-
l-leucyl-L-leucyl-norvaline: MDL 28170. carbobenzoxy-valinyl-
phenylalaninal; 4-HNE. 4-hydroxynonenal; PAGE, polyacrylamide gel 
electrophoresis; CHAPS, 3-1(3-cholamidopropyl)dimethyiammonioJ-l-
propanesulfonic acid; ANOV A. analysis of variance, 
activity, as hypothesized 0, 2, 4, 9, 10), then two predictions 
should be valid, First, individual A series and J series PG 
should act rather uniformly on the cellular processes they 
affect. Second, their cellular effects should be self-consistent 
with established models of NFKB and p53 function. However, 
not all experiments affirm these predictions, For example, the 
A and J series PG both repress NFKB transcription and inhibit 
IKB kinase (1,2); however, only tl.12- PGJ 2 is anti-inflammatory 
( 11 J. Likewise, the A and J series PG both repress p53 tran-
scription; however, only the A series PG antagonize p53-de-
pendent apoptosis (Ref 4 and see below J. 
Herein we report the discovery of a molecular mechanism 
that clarifies the distinctive cellular effects of cyclopentenone 
PG. Namely, J series PG preferentially inhibit the ubiquitin 
isopeptidase activity (ubiquitin-specific protease I of the protea-
some pathway. This pathway is the major nonlysosomal deg-
radation pathway in cells (12, 13). The degradation of target 
proteins via this pathway largely depends on their covalent 
modification with a ubiquitin polymer, This polymer consists of 
ubiquitin (S,5 kDal subunits that are covalently attached via 
Isopeptide bonds between the COOH terminus of one ubiquitin 
and the lysine €-amino group of another ubiqui tin. In turn, this 
polymer is covalently attached to a lysine €-amino group on the 
target protein via another isopeptide bond. UbiqUitin isopepti-
dases are a large family of cysteine hydrolases that preferen-
tially cleave these isopeptide bonds (14), 
We demonstrate that inhibition of ubiquitin isopeptidase 
activity by PG depends on nuances of olefin-ketone conjuga-
tion, J series PG with a cross-conjugated U',{3-unsaturated di-
enone are more efficacious inhibitors compared with A series 
PC with a a,.l3-unsaturated ketone (Fig, I), We further 
demonstrate J series PG cause apoptosis, concurrently 
with inhibition of isopeptidase activity, and independently of 
p53-mediated gene transactivation, Our discovery has partic-
ular implications for the development of novel antineoplastic 
agents that are effective against cancers with dysfunctional 
p53 pathways, 
EXPERIMENTAL PROCEDURES 
Materials-We used Dulbecco's minimum essential medium and me-
dia supplement~ (Life Technologies. Inc.); tl12-PGJ~, PCA" PGA" 
PGB" PGE" and 15-keto-PGE~ (Cayman Chemicals. Ann Arbor, M1l; 
etoposide (Sigma); complete protease inhibitor mixture and FuGene-6 
transfeclion reagent (Roche Molecular Biochemicals); enhanced cheml' 
luminescence reagents (Amersham Pharmacia); luclferase reporter 
lysis buffer and reporter detection reagents (Promega); antibodies 
directed against p53. PAb240, FL393, and DO-1 (Santa Cruz Biotech, 
nology). Phospho-p53 ISer") (Cell Signaling Technology), and PAb1620 
(Oncogene Research Products); antibodies against p21WI\FI1<'ll'l (C-19. 
Santa Cruz Biotechnology) and ubiquitin (Ul>1-1. Zymed LaboratorieH 
Inc,); horseradish peroxidase-conjugated secondary antibodies; protein 
AlG PLUS-Agarose (Santa Cruz Biotechnology); z,LLE-MCA. z-LLL-
MCA. MG115. Ac-DEVD-MCA (Peptides International); LLVY-MCA. 
z,LRGG-~1CA (Alexis CorporatIOn); MDL 28170 (z-VF-CHO, Calbio-
chem); Ub- 125I-lysozyme (gift from Dr. Martin Rechsteiner. Department 
of Biochemistry, University of Utah); annexin V, Alexa Fluor® 488 
conjugate (Molecular Probes, Inc.); a luciferase p53 cis reporter con, 
30366 Thi. paper is available on line at http://www.jbc.org 
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FIG. 1. Structures of cyclopentenone prostaglandins. Asterisks 
electrophilic carbon(s). PGB 1 is relatively inert in physiological 
struct (p53-Luc, Stratagene); ~-galactoBidase expression vector (pSV-~; 
Promega); and pC53-SN3 (wild type) and pC53-SCX3 (V143A mutant) 
p53 constructs «(15, 16), gift from Dr. Bert Vogelstein, Johns Hopkins 
University, Baltimore, MOl. 
Cell Culture-We maintained RKO, RKO-E6 (gift from Dr. Mark 
Meuth, Institute for Cancer Studies, University of Sheffield, Shef-
field, United Kingdom), Ts20 cells (17) (gift fro~ Dr. Harvey Ozer, 
Department of Microbiology and Molecular Genetics, UMDNJ-New 
Jersey Medical School, Newark, NJ) in Dulbecco's minimum essential 
medium in a humidified incubator with 5')1; CO2 , We supplemented 
the media with 2 mM L-glutamine, 1 mM sodium pyruvate. 50 units/ml 
penicillin, and streptomycin, and 10'* (v/v) fetal bovine serum. We 
maintained Ts20 cells at 32 ·C (permissive temperature) but 
them in a 40 ·C incubator (non permissive temperature) to 
the El ubiquitin-activating enzyme in experiments designed to ob· 
serve disassembly of polyubiquitinated proteins (17). All other cells 
were maintained at 37 ·C. 
p53·DNA Binding and Tronsactivation-We measured p53-D:\A 
binding activity via electrophoretic mobility shift We isolated 
nuclei and generat .. d protein·DNA complexes as previously 
(I8). We used the wild type p53 consensus, 5'-AGC TGG ACA TGC CCG 
GGC ATG TCC-3', double-stranded oligonucleotide, and a mutant olio 
gonucleotide, 5'-AGe TGG ATC GeC CCG GGC ATG TeC-3' (Geneka), 
to evaluate sequence specific p53-DNA binding. We incubated 25,000 
cpm (2 x 107 cpm/;.<g) of the '"P-Iabeled oligonucleotide probe with 1 ;.<g 
of nuclear extract. We fractionated samples on a nondenaturing 6o/c 
TBE (45 mM Tris borate, 1 mM EDTA)'polyacrylamide We exposed 
Kodak XAR film to the gel for 8-24 h at -70·C to p53-DNA 
complexes. 
We transfected RKO cells with a p53-luciferase reporter construct to 
measure p53-dependent transactivation (4). We used expression of an 
independently transfected l3-galactosidase gene to normalize for trans· 
fection efficiency and cell death. 
Immurwchemical Detection of Proteins-After treating cells with the 
indicated compounds for the indicated times, we removed the medium 
and cells in 50 mM Tria, pH 7.4.100 mM NaC\, 2 mM EDTA with 
0.1% deoxycholate, 1 X complete protease inhibitor mixture. 
We measured protein concentration by the Bradford method. We frac-
tionated equal portions of the total cell lysate from each sample (12.5 ;.<g 
of protein) by SDS-PAGE. We transferred proteins to polyvinylidene 
difluoride blocked with 5% (w/v) nonfat dry milk in Tris-buffered saline 
T (20 mM Tris'HCI, pH 7.5, 100 mM sodium chloride, 0.59'c (v/v) Tween 
20). We measured proteins immunochemically by using primary anti· 
bodies directed against p53 (1:4,000), p21WAFlJCIPI (1:5,000), and 
uitin (1:1000), followed by horseradish peroxidase-conjugated 
ary antibodies (1:4000). We detected antigen·antibody complexes with 
enhanced chemiluminescence reagents. We scanned gels and quantified 
intensities using Kodak 10 Image Analysis Software. 
Immurwprecipitation of p53-We treated RKO and RKO·E6 cells 
with the indicated compounds for the indicated times. We lysed cells in 
250 mM sucrose, 50 mM Tris, pH 7.4, 25 mM KCI, 5 mM MgCI 2 • 1 mM 
EDTA. Ix complete protease inhibitor, 1 mM NaF, and 1 mM sodium 
orthovanadate. We sonicated the lysate twice for 5 s at 4 ·C. After 
centrifugation at 13,000 x g, we incubated samples containing 200 ;.<g 
of total protein, in 1 ml of lysis buffer, with 1 jJ.g of primary antIbody, 
and 20 jJ.1 of protein A/G PLUS-Agarose overnight at 4 'C on a rocker. 
PAb 1620 precipitates p53 occurring in a wild type conformation; PAb 
240 precipitates p53 in a mutant conformation 09-21). DO-I precipi· 
tates p53 occurring in either conformation or as a p53-ubiquitin conju-
gate. We centrifuged the samples at 2500 x g to isolate the antigen· 
antibody·bead complexes. We washed the immunoprecipitate four 
times with 1 ml of phosphate·buffered saline, 0.4'* Tween 20. We then 
measured p53 or ubiquitin by immunochemical analysis with antibod-
ies for p53 (FL·393) and ubiquitin (ubi·n. respectively. Note that PAb 
240 and PAb 1620 are monoclonal antibodies, despite their annotation. 
Apoptosis Assays-We incubated 5 x 104 RKO cells. plated on a 
Lab-Tek® II Chamber Slide™ (Nalge Nunc International Corp.), with 
the mdicated compounds for the indicated times and then washed the 
cells twice with phosphate-buffered salme. We added 100 J.L1 of annexin-
binding buffer (10 mM HEPES, 140 mM NaCl, and 2.5 mM CaCI2 • pH 7.4) 
and 5 J.L1 of Alexa Fluo~ 488-1abeled annexin V and incubated samples 
for 15 min at room temperature. We washed the cells twice with 400 
of annexin-binding buffer and resuspended them in 15 J.LI of 
annexin-binding buffer:water. We stained the cells with propidium 
iodIde (1 ;.<M) and Hoechst 33342 (l illl) and eXaInmed them by fluores· 
cence microscopy. We determined caspase activity and DNA fragmen· 
tation as described previously (22). 
p21WAFJiCIPJ Gene Expression-We determined p21 WM'liCII'1 mRNA 
expression from eDNA microarray experiments (4) 
20 S Proteasome Activity Assays-We determined 20 S proteasome 
catalytic activity by monitoring the cleavage of substrates for the 
post·glutamyl peptidase (z·LLE·MCA) and chymotrypsin-like (z-LLL-
MeA and LLVY·MCA) proteolytic activities of the 20 S proteasome. 
Briefly, we incubated RKO cells with the indicated for the 
indicated times. We lysed cells in 250 ;.<1 of 25 mM 5 mM 
0.1')1; CHAPS, 5 mM ATP. pH 7.5 with 2 mM dithlOthreltol 
just prior to lysis. We sonicated lysates and dispensed 45-J.LI 
aliquots into four wells of a 96·well We added 5 J.LI of 
each proteasome (500 ;.<M in lysis to separate 45-;.<1 
samples (final substrate concentration: 50 J.LM). We incubated the 
assay mixtures at 37 'C for 15 min and quantified fluorescence (sub-
strate cleavage) by exciting the samples at A = 360 nm and monitor-
ing the emission at A 460 nm. 
26 S Proteasom!! Activity Assay-We determined the 26 S proteaBome 
regulatory activity by monitoring the cleavage of Ub- '25I-lysozyme, 
prepared as described previously (23). We incubated RKO cells with the 
indicated compounds for the indicated times. To monitor 26 S protea· 
some regulatory activity. we incubated 22.5 ;.<1 of lysate. 2.5 ;.<1 of an 
ATP regenerating system (0.5 mM ATP, 60 J.Lg/ml creatine phosphoki-
nase, 6.6 mM phosphocreatine, 10 mM Tris-HCI. 0.5 mM MgCI 2• 1 mM 
KCl, 0.05 mM dithiothreitoll, and 25 ;.<1 of l·l"I-lysozyme·ubiquitin con-
jugates (136 cpm/ ;.<\). After 30 min at 37 ·C, we removed a 20·J.LI sample 
and added 400 ;.<1 of bovine serum albumin solution (1 ~Ii. bovine serum 
albumin in 10 mM Tris. pH 7.5, 0.02% azide). We then isolated the acid 
soluble fraction by trichloroacetic acid precipitation (50 ;.<1 100'1( w/v 
trichloroacetic acid, on ice, 15 min) and centrifugation for 15 min at 
16.000 g. We determined the amount of 12['1 in the supernatant by 'Y 
spectrometry and calculated the percentage of soluble '~5I (supernatant 
12511total 1251) to determine the extent of substrate proteolysis. 
lsopeptidase Activity Assay-We determined activity by 
monitoring cleavage of a peptide substrate that mimics 
the carboxyl terminus of ubi quit in, which is involved in isopeptide bond 
formation. We observed that this subsfrate was subject to degradation 
by the proteasome; therefore. we incubated RKO celllysates <0.5 J.Lglml 
in 25 mM HEPES, 5 mM EDTA, 0.1% CHAPS, 5 mM ATP, pH 7.5) with 
30 ;.<M MG1l5 to inhibit proteasome activity (>90'*, inhibition was 
achieved). These conditions were used to eliminate background proteo-
lytic activity and to permit selective determination of isopeptidase 
activity. We next added various concentrations of prostaglandins to 
identify lsopeptidase inhibitory activity. Prostaglandins were incubated 
for 0.5 h on ice prior to substrate addition. We incubated the assay 
mIxtures at 37'C for 3 h and quantified fluorescence as described 
above. Lysates were also monitored for proieasome activity to ensure 
that the isopeptidase inhibitory effect Been with the prostaglandins was 
not due to additive proteasome inhibition. 
RESULTS 
A.12-PGJ 2 Impairs the p53 Tumor Suppressor while Inducing 
Apoptosis Concurrently-PGA I and A2 can repress transcrip-
tion by p53, thereby antagonizing p53-dependent apoptosis (4). 
If their electrophilic cyclopentenone ring confers this activity, 
as we hypothesized, then A.12-PGJ2 should act analogously to 
PGA1 and PG~. Consistent with our hypothesis, we observed 
that RKO cells exposed to A.12-PGJ2 acquired p53 that was 
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FIG. 2. A12.PGJ2 impairs p53 conformation and transactiva· 
tion. In panels A-C, RKO cells were Incubated with ~12·PGJ2 (0-60 
/-LM, 6 h, 37 ·e), A, ~12·PGJ2 causes p53 to obtain a mutant conforma-
tion. The p53 protein in cell lysates was immunoprecipitated with 
conformationally sensitive antibodIes that distinguish between the na· 
tive (Pab1620) and mutant (Pab240) conformers of p53, Positive can· 
trois were RKO cells transfected with plasm ids that express either a 
conformational mutant ofp53 (p53 fV143A)) or wild type p53 (p53 (wI)), 
.l12-PGJ2 inhibits a key step in p53 activation, serine 15 phospho· 
Total p53 protein and p53 phosphorylated at serine 15 (P04 • 
p53) were determined by Western blot analysis, Densitometry 
was used to obtain the PO.·Ser'o p53/total p53 ratios. This ratio in lane 
2 (the positive controL etoposide) is designated as 1 for connpa.risl)fl 
purposes, C, ,a,12·PGJ2 inhibits the transcriptional activity .:112· 
PGJ~ inhibited the basal transactivation (0) and eto'DOf!id'l·irlduced 
trans activation (Al of a p53·luciferase reporter 
Data are the mean :! S.D., n = 3 experiments. 
DNA binding by p53. RKO cells were incubated 6 h WIth Me2SO 
vehicle, 50 /-LM etoposide, 60 /-LM .112·PGJ2, alone, or combined WIth 50 
/-LM etoposide, Nuclear extracts from these cells were incubated with 
:!2P·labeled oligonucleotide containmg a consensus binding sIte for p53, 
and as indicated, with PAB 421, an antibody that binds p53, excess 
cold oligonucleotide (competitor) identical to the 32P·labeled ollgonu· 
cleotide, or excess cold oligonucleotide (mutant) differing in sequence 
from 32P·labeled oligonucleotide, Arrows indicate p53·J "P·labeled 01· 
igonucleotide complexes, NS = nonspecific labeling; FP free :J2p. 
labeled oligonucleotide, 
transcriptionally inactive, as determined by a variety of assays. 
~12-PGJ2 transforms p53 protein in RKO cells from its wild 
type, native conformation into a mutant conformation (Fig. 2A, 
lanes 1-3). This mutant p53 conformation is a less efficient 
substrate for serine 15 phosphorylation. Phosphorylation of 
this residue on p53 is an early event in p53 activation, Etopo. 
side increased total and phosphoserine 15 p53 in RKO cells 
relative to the control (Fig. 2B, lanes 1 and 2), However, co· 
incubation with 20-60 p..M ~12-PGJ2 reduced serine 15 phos-
phorylation (Fig. 2B, lanes 3 and 4). The consequences of in· 
hibiting this activating step are reflected in the transactivating 
ability of p53, Etoposide·stimulated transcription of a p53-de-
pendent reporter was potently inhibited by 6-60 IJ-M ~12-
PGJ2 (Fig. 2C).1t apparent why p53 failed to transcribe 
genes when we examined its ability to bind an oligonucleotide 
containing a p53 consensus binding sequence, In this assay, 
etoposide (50 p..M) promoted the formation of p53-32P-Iabeled 
oligonucleotide complexes (Fig. 2D, lane 6) that could be super· 
shifted with antibody (Fig. W, lane 3), and competi-
excess "cold" oligonucleotide (Fig. 2D, lane 
5). Excess cold mutant oligonucleotide inhibited only the non· 
formation of p53-32P~labeled oligonucleotide complexes 
W, lane 4), However, 60 p..M .:H2-PGJ2, alone (Fig. W, 
lane 7) or combined with etoposide (Fig. 2D, lane 8) inhibited 
the formation of p53-32P-Iabeled oligonucleotide complexes, 
These data suggest that, in terms of their pharmacological 
effects on p53, J series PG are quantitatively and qualitatively 
indistinguishable from A series PG. Cyclopentenone PG have 
similar effects on wild type p53 in cell lines other than RKO 
cells, including HCT 116, A549, and MCF-7 cells (data not 
shown). 
In contrast to their uniform effe<:ts on p53 function, A and J 
series PG had divergent effects on apoptosis. As expected for 
agents that impair p53 function, PGAI and PGA2 do not cause 
apoptosis (Fig, 3), However, ~12 PGJ2 causes apoptosis, charac· 
terized by nucleosomal fragmentation, activation of caspase-3, 
and cellular association of annexin V (Fig. 3, A-CL The induc-
tion of apoptosis by J.12.PGJ2 , concurrent with its impairment 
of p53 function in RKO cells is difficult to reconcile with the 
conventional model of p53 tumor suppression (6, 7). 
p21WAFJlCIPJ Protein Levels Rise, Despite the Decline in Its 
Transcription-As expected. transcription of endogenous 
regulated by p53, typified by p21 wAn/eIPI, declined in 
cells incubated with ~12-PGJ2 (Fig. 4A), However, we noticed 
that these cells continued to accumulate p21WAFlJClI'1 protein 
(Fig. 4B, lane 4) This implies that toI2-PGJ2 had slowed the 
rate of p21 WAFlICIPl protein degradation. This effect is distinc· 
tive for ~12-PGJ2; mRNA and protein levels of p21wAFlICIPl 
fall, in parallel, in RKO cells treated with PGAI or PGAz (4) 
(Fig, 4A and 4B, lanes 2 and 3). Proteolysis via the ubiquitin· 
dependent proteasome pathway modulates the activity of sev-
eral transcription factors, tumor suppressors, and regulatory 
proteins, including p21WAFI/ClPl and p53 (24, 25), Inhibitors of 
the 20 S proteasome catalytic activity can also cause 
(26). Therefore, we hypothesized that ~12-PGJ2 
ubiquitin·dependent 26 S proteasome pathway. 
We used RKO and RKO·E6 cells as a model to test this 
hypothesis, RKO·E6 cells are derived from isogenic RKO cells 
stably transfected with the E6 oncoprotein. The E6 oncoprotein 
is an ubiquitin·conjugating enzyme that hastens proteasome· 
mediated degradation of the p53 tumor suppressor protein (27). 
One predicts that RKO·E6 cells will accumulate p53 to a lesser 
extent than will RKO cells under various conditions ranging 
from basal to genomic stress, In contrast, one predicts that both 
cell lines will accumulate p53 to a similar extent if .-l12-PGJ2 
inhibits the ubiquitin·dependent proteasome pathway, 
~12·PGJ2 Inhibits the Ubiquitin·dependent Proteasome 
Pathway-Consistent with our prediction, the ratio of p53 pro-
tein in RKO-E6 cellslRKO cells was lower in every case tested, 
except cells incubated with ~12-PGJ2 (Fig. 5A, lane 5), Note 
that RKO·E6 cells incubated with etoposide accumulate 3-fold 
less p53 compared with isogeruc RKO cells (Fig. 5A, lane 2), 
confirming that the E6 oncoprotein hastens the degradation of 
p53, Note also that RKO-E6 cells incubated with PGA I and 
PGA2 accumulated negligible amounts of compared with 
the vehicle control (Fig, 5A, lanes 3 4 versus lane n, 
indicating that these cyclopentenone PG do not inhibit protea· 
some·mediated degradation of p53 as efficaciously as ~12· 
PGJz' Both RKO and RKO·E6 cells incubated with .-l12.PGJ2 
accumulated appreciable p53 protein (-2-3-fold compared 
with vehicle control (Fig. 5A, lane 5 versus lane I!. A separate 
control showed that the 20 S proteasome inhibitor, 
MG115, RKO and RKO-E6 cells in a manner analo· 
gous to ~12.PGJ2 (Fig, 5A, lane 6 versus lane 5), 
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FIG. 3. A12·PGJ2 causes apoptosis despite inactivating p53. 
mediated transcription. A. only il12-PGJ2 causes nucle080mal DNA 
fragmentation. RKO cells were treated with vehicle or 20 jJ.M ilI2-PGJ2, 
PGA" or PGAl for 16 h. DNA was isolated from nuclear extracts, 
subjected to electrophoresis on a 1.5% agar08e gel. and visualized by 
staining with ethidium bromide. B, only ilI2-PGJz causes the activation 
of caspase-3. RKO cells were treated for 16 h with either vehicle 1.),20 
p.M ilI2-PGJ2 (0), or PGA, (.), and caspase-3 activity was determined. 
Data are the mean S.D., n 3 experiments. C, only ilI2-PGJ2 causes 
extemalization of cellular phosphatidylserine. Extemalization of phos· 
phatidylserine is a marker for apoptosis. RKO cells were treated with 
vehicle (panel 0, 20 jJ.M PGAl (panel ii), 20 jJ.M AI2-PGJ2 (panel iii), or 
50 IJ.M etoposide (pan:el iv) for 16 h. Fluorescence microscopy was used 
to determine the extent Alexa Fluor® 4BB·labeled annexin V lanti· 
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FIG. 4. A12.PGJ2 causes p21 WAFlICIPl protein accumulation de· 
spite antagonizing p21 transcription. RKO cells were treated with 
etoposide (50 p.M), PGA, (60 ILM). PGA2 (60 14M), or .H2-PGJ, (60 ILMJ. for 
6 h. A, total RNA was isolated for microarray analysis to determine 
relative p21 mlU.JA expression. B, cellular levels of p5J and p21 WA'-lI('!1' I 
protein were determined by itnmunochemical analysis. 
Cellular p53 proteins are targeted for 26 S proteasome-
mediated degradation by conjugation with polyubiquitin (28) 
Consistent with our hypothesis, iH2-PCJ2 caused RKO and 
RKO-E6 cells to accumulate high molecular weight p53 epitopes. 
recognized by anti·p53 antibody (Fig. 5B,lanes 5 and 10). Immu-
noprecipitation with anti·p53 antibody, followed by SDS·PACE 
and immunochemical analysis with anti-ubiquitin antibody, 
confirmed that these high molecular weight p53 epitopes were 
polyubiquitinated isoforms of p53 (Fig. 5C, lanes 5 and 6) The 
accumulation of p53-polyubiquitin isoforms in r'ig. 5C signifies 
that 1l12-PCJz inhibits the ubiquitin-dependent proteasome 
pathway in a concentration·dependent manner. This effect is not 
restricted to p53 or to RKO cells; 1l12-PCJ2 also caused a corre-
sponding accumulation of poly ubi quit in conjugates in Hlr60 cells 
that lack p53 alleles (data not shown!. Polyubiquitin conjugate 
accumulation was most pronounced in cells treated with J series 
PC 5D, lanes 2-4) compared with PCA I , PCA,!. PCB l . 
")·K.,,'!)·,r" .... ~_ or PCE2 (Fig, 5D, lanes 5-9), J series PC share 
crc,ss"colnjulgated unsaturated ketone, while the other PC do 
not have chemical feature. Note that while PCJ2 does not 
possess cross-conjugation, it is rapidly converted to 1l12-PGJ2 
in situ (29). 
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FIG. 5 . .112-PGJ2 inhibits the ubiq· 
uitin-dependent proteasome pathway 
in RKO and RKO-E6 cells. RKO and/or 
RKO-ES cells were treated with the indi-
cated PG (20 JLM. S h) or etoJl<l8ide (50 JLM. 
S h). A. A12-PGJ~ inhibits HPV-ES-medi· 
ated degradation of p53. Cellular levels of 
p53 protein were determined by immuno-
chemical analysis. MG1l5 (20 JLM, 4 h) was 
used as a Jl<l8itive control for inhibiting pro-
teasome-mediated degradation of p53. 
Densitometric analysis was used to obtain 
relative p53 abundance ratios. B. A12-PGJ2 
causes the accumulation of high molecular 
weight p53. Prolonged exposure of the West-
ern blot in A was used to identify high 
molecular weight epitopes recognized by an· 
ti·p53. C. A12·PGJ2 causes the accumula· 
tion of polyubiquitinated p53. p53 was 
immunoprecipitated with anti-p53, fraction-
ated by SDS-PAGE. and analyzed immuno-
chemically with an antibody to ubiquitin. D, 
only J series PG cause the accumulation of 
polyubiquitin conjugates. Whole cell lysates 
were collected from RKO cells that were 









It is unlikely that .:H2-PGJz inactivated the E6 oncoprotein. 
or other endogenous ubiquitin ligases, ubiquitin-activating en-
zymes, or ubiquitin-conjugating enzymes, because cells incu-
bated with ~12-PGJ 2 accumulated p53-polyubiquitin conju-
gates. This implies that these enzymes are still functional in 
their roles of catalyzing ubiquitin conjugation (Fig. 5B). ~12-
PGJ2 retained its potency and efficacy as an apoptotic agonist 
in RKO-E6 cells (data not shown). This is consistent with our 
conclusion that PGJ2 causes apoptosis via a process that is 
independent of p53 transcription. 
t:..12-PGJ 2 Inhibits the Proteason.e Pathway at a Site Distinct 
from the 26 S Proteasome-The 26 S proteasome consists of 
multiple subunits. including two 19 S regulatory subunits that 
recognize and bind polyubiquitinated protein substrates, and a 
20 S proteolytic subunit having broad substrate specificity (24J. 
MG115, which acts at the 20 S catalytic site, inhibited hydrol· 
ysis of several proteasome substrates in whole celllysates. We 
examined hydrolysis of substrates for the chymotrypsin-like 
(z-LLL-MCA and LLVY-MCAl and post-glutamyJ peptidase (z· 
LLE-MCAJ proteolytic activities, as well as a 19 S regulatory 
subunit-dependent substrate, Ub-125I-Iysozyme (Fig. 6A). At a 
concentration exceeding that which causes polyubiquitin con-
jugate accumulation in intact cells, ~12-PGJ2 (60 J..LM) did not 
significantly inhibit hydrolysis of any of these proteasome sub-
strates (Fig. 6A). In other words, MG115 (20 J..LM) is significantly 
more efficacious (~90%) than ~12-PGJ2 (:520%) at inhibiting 
the catalytic activity of the 26 S proteasome. Lactacystin, an-
other agent that acts at the 20 S catalytic site, behaved simi-
larly (data not shown). We noted that the differences in efficacy 
between MG115 and Ll12-PGJ2 as proteasome inhibitors (Fig. 
6A) did not correlate with the extent or rate of polyubiquitin 
accumulation in cells. A dose-response experiment showed 
that, despite being a weaker proteasome inhibitor. Ll12·PGJz 
(6-60 J..LM) (Fig. 6B, lanes 5-7) caused intracellular polyubiq-
uitin accumulation to a greater extent than MG 115 (2~20 J..LMJ 
(Fig. 6B, lanes 2-4>. Furthermore, we observed that the molec-
ular weight distribution of poly ubi quit in differed between RKO 
cells treated with MG1l5 and t:..12-PGJz. When incubated with 
20 J..LM MG115, RKO cells accumulated polyubiquitin distrib-
uted around a maximum of -160 kDa. When incubated with 60 
J..LM t:..12-PGJ2, RKO cells accumulated polyubiquitin distrib· 
uted around a maximum of -250 kDa (Fig. 6C). Collectively, 
these data (Figs. 5 and 6) suggest that ~12-PGJ2 inhibits the 
terminal step in the proteasome pathway: isopeptidase-medi-
ated disassembly of polyubiquitin. 
j,12·PGJ 2 Inhibits the Isopeptidase ActiVIty of the Protea· 
some Pathway-To test our hypothesis, we sought an experi. 
mental system that would allow us to examine polyubiquitin 
disassembly in the absence of de novo ubiquitin conjugation. 
The murine cell line, ts20, harbors a temperature-sensitive E1 
ubiquitin-activating enzyme that is catalytically impaired at 
the nonpermissive temperature, 40 ec (17). We first uniformly 
accumulated polyubiquitinated proteins at the permissive tern· 
perature (32 eCl by incubating ts20 cells with MG1l5 (1 J..LM, 
12 h). We then added fresh media containing either MG1l5 (6 
J..LM) or .:H2·PGJ2 (20 J..LMl and immediately incubated the sam-
ples at the nonpermissive temperature and monitored polyu-
biquitin disassembly by ubiquitin isopeptidases (Fig. 7A). Un-
der these conditions, tl12-PGJ:J slowed the rate of polyubiquitin 
disassembly significantly (Fig. 7B,lanes 8-101 compared with 
MezSO (Fig. 7B, lanes 2-4) or MG1l5 (Fig. 7B, lanes 5-7J. 
Densitometric analysis of the polyubiquitinated proteins in 
Fig. 7A showed that, in the absence of de novo ubiqultin con-
jugation, polyubiquitin disappeared by first-order kinetics with 
a half-life (tv') == 6 h in t820 cells treated with 20 J..LM LH2-PGJz 
(~'ig. 7Cl. This rate is 3-fold slower than the rate of polyubiq-
uitin disappearance, tv., 2 h, in ts20 cells treated with 
MG1l5. consistent with :'12-PGJz and MG115 having different 
sites of action. We note that this effect could not be reproduced 
with a cell-penetrable, peptide inhibitor of cathepsin Band 
calpains (MOL 28170 (30»), indicating that polyubiquitin dis-
assembly does not reflect activity of other major cellular pro-
teolytic pathways (data not shown). We also note that ts20 cells 
respond to PG treatment in a manner similar to RKO cells; 
t:..12-PGJ2 causes a greater accumulation of polyubiquitin con-
jugates in ts20 cells than an equimolar concentration of MG 115 
(data not shown). 
Isopeptidases comprise a large family of cysteine proteases. 
Currently, little is known about the substrate specificity of the 
individual members of this family. Therefore, we measured 
inhibition of isopeptidase activity by quantifying the degrada-
tion of a general isopeptidase substrate, z-LRGG-MCA, that 
mimics the ubiquitin COOH-terminal isopeptide linkage (Fig. 
8). We observed a concentration-dependent inhibition ofisopep· 
tidase substrate degradation with ~12-PGJ2' while PGA., 
PGB j , PGE2, and 15-keto-PGK,! demonstrated no inhibitory 
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FIG. 6 . .1.12·PGJ2 inhibits the ubiquitin-dependent proteasome 
pathway at a site distinct from the proteasome. A, 1l12-PGJ~ does 
not inhibit the catalytic or regulatory activities of the proteasome. RKO 
cells were incubated for 6 h at 37'C with Me 2SO (vehicle), 20 J.L. .. ! 
MG1l5, or 60 p,M A12-PGJ2 • Celllysates were analyzed for proteolysis 
of catalytic subunit substrates (ZLLE-MCA (II), ZLLL·MCA (0). and 
LLVY·MCA (lSi)) and a regulatory subunit-dependent substrate (Ub· 
l~f·l·lysozyme (11). Data are the mean S.D., n 3, with statistical 
significance indicated (*, ANOVA, p < 0.05). B, despite being a weak 
proteasome inhibitor, tl.12·PGJ2 is potent at causing polyubiqultin ac-
cumulation, RKO cells were incubated for 6 h at 37 'C with Me,SO 
vehicle, 6-60 j.tM MGII5, or 6-60 j.tM A12-PGJ2 • Cellular accumulation 
of polyubiquitinated proteins was determined by Western blot analysis 
with anti-ubiquitin antibody. C, AI2-PGJ2 causes the accumulation of 
high molecular weight species of polyubiquitin. The Western blot In B 
was quantitated by densitometry to determine the molecular weight 
distribution of polyubiquitinated species that accumulated in RKO cells 
aner incubation with Me2SO (lighlgray stippled trace), 60 p,M tl.12-PGJt (solid black trace), or 20 j.tM MG 115 (darker gray trace). Arrows indicate 
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FIG. 7. J.12-PGJ. inhibits polyubiquitin disassembly in ts20 
cells. A. schematlc representatIOn of the experimental conditions used 
m the polyubiquitm disassembly assay. B . .:l12-PGJ1 inhibits the dis-
assembly of polyublquitin chains. Ts20 cells were incubated with 1 !AM 
MG1l5 at 32'C for 12 h. Under these conditions. the temperature-
sensitive El ubiquitln-activating enzyme is active. and t520 cells accu-
mulate polyubiquitinated proteins. After the mitlal incubation, fresh 
medium was added containing either MezSO, MG1l5 (6 !AM), or .l12-
PGJ·L (20 p,Ml, and the ts20 cells were incubated for an additional 0-6 
hat 40 ·C. At 40 'C. the El enzvme becomes inactivated and ts20 cells 
stop assemblmg polyubiquitin, thereby facilitating the measurement of 
polyubiquitin disassembly, C, A12-PGJ:l increases the half-life ofpolyu-
biquitin in cells. The Western blot in B was quantitated by densltom-
etry to determine the half-life of polyubiquitin in ts20 cells treated 
with Me:lSO (Al, 6 !AM MG1I5 or 20 !AM AIZ-PGJ:l (.1. 100'); 
defined as the total at time O. Data are fit to first-order 
exponential decay curves represent the mean c: S.D .. /I 3 exper-
iments. with statistical significance mdicated C", AN OVA, p 0.05), 
activity in this assay. We note that MDL 28170 (l80 /-LM) did not 
impair the degradation ofz-LRGG-MCA under these conditions 
(data not shown). Furthermore .H2·PGJ2 ($180 /-LM) did not 
inhibit the degradation of a proteasome substrate, z-LLE-MCA, 
or a caspase-3 substrate, Ac-DEVD-MCA, indicating selectivity 
for the inhibition of isopeptidase activity (data not shown!. 
Due to recent findings, we examined the effects of 4-hy-
droxynonenal (4-HNE) treatment on the disassembly of polyu-
biquitin in ts20 cells. Electrophilic prostaglandins can generate 
oxidized lipids, such as 4-HNE (26-28), which is known to 
inhibit proteasome activity at millimolar concentrations (31-
35). Like Ll12-PGJ2, this compound can form covalent adducts 
with proteins. If generation of oxidized lipids or covalent mod-
ification of target proteins are mechanisms by which LlI2-PGJ2 
inhibits the disassembly of polyubiquitinated substrates, then 
4-HNE should act in a manner analogous to j,12-PGJ~. How-
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FIG, 8. A12-PGJ2 inhibits isopeptidase activity in RKO cell 
Iysates. Cell Iysates were obtained from RKO cells (0.5 iJ.glmll and 
treated with MGll5 (30 !J.Ml to prevent proteasome-mediated degrada-
tion of the isopeptidase substrate, z-LRQG.AMC, These lysates were 
then co-incubated with 6-180 !J.M ,H2-PGJ2 (.). 6-180 iJ.M PGA, ('::"), 
6-180 iJ.M PGB, (0), 180 iJ.M PGE, (v), or 180 !J.M 15-keto-PGE~ (0) for 
0.5 h on ice. lsopeptidase Bubstrate (z-LRGG-A.'vtC) was added. and the 
reaction mixture was incubated for 3 h at 37 ·C. Sample fluorescence 
was monitored as before. Date are fit to first-order exponential decay 
curves and represent the mean S.D., n 3 experiments. with statis-
tical significance indicated (*, ANOVA, p < 0.05). 
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FIG. 9. 4·Hydroxynonenal does not inhibit polyubiquitin dis-
assembly in ts20 cells. A, experimental conditions were set as in Fig, 
7. At timeD, medium containing MGl15 (l!J.M. 12 h) was aspirated from 
ts20 cells and fresh medium containing either Me,SO or 4-HNE was 
added. The cells were then incubated at 40 'C to facilitate the monitor-
ing of polyubiquitin disassembly. B, the Western blot in A was quanti. 
tated by densitometry to determine the extent of polyublquitin disas-
sembly in ts20 cells treated with Me,J30 (.) or 20 iJ.M 4-HNE (e), 100% 
is defined as the total polyubiquitin at time 0, Data are the mean 
S.D., n = 3 experiments. 
• Protein Target 
Mono ubiquitin 
... ~~~ Polyubiquitin 
\ Target remnant 
Peptide + .~ 
Fragments '\ 
FIG. 10. Schematic diagram of the ubiquitin-dependent pro-
teasome pathway and site of action of A12-PGJ2 • 
ever, we did not observe a significant inhibition of polyubiq-
uitin disassembly by 4-HNE (Fig. 9, lanes 5-7), even at cyto-
toxic concentrations, when compared with control (Fig. 9, lanes 
2-4 J. Furthermore, 4-HNE (S 180 14M) had no effect on the 
degradation of the isopeptidase substrate, z-LRGG-AMC (data 
not shown>. Combined, these data suggest that .H2-PGJ2 does 
not mediate these effects through oxidized lipids such as 
4-HNE. 
DISCUSSION 
Herein we report that ~12-PGJ2 causes apoptosis independ-
ently of p53-mediated transcription. We also provide evidence 
that ~12-PGJ2 inhibits the proteasome pathway via a novel 
mechanism: inhibition of cellular ubiquitin isopeptidase activ-
ity (Fig. 10). Proteasome pathway inhibitors can induce apo-
ptosis independently of p53 (36, 37), suggesting that inhibition 
of cellular isopeptidase activity is a mechanism by which ~12-
PGJ2 causes apoptosis, 
Inhibition of cellular ubiquitin isopeptidase activity should 
have five predictable effects. First, polyubiquitin and/or polyu-
biquitinated proteins should accumulate (Figs. 5, B-D, and 
6Bl. Second, the cellular pool of monomeric ubiquitin should 
diminish and its depletion should slow the rate of ubiquitin-
protein conjugation, leading to accumulation of unmodified 
protein (e,g. p53J (Fig. 5A). Third, cells with active 26 S pro-
teasome and inactive isopeptidases (i.e. ~12-PGJ2 treatment) 
should retain polyubiquitin-protein conjugates differing in 
composition compared with cells with active isopeptidases and 
inactive 26 S proteasome (i.e. MG115 treatment> !Fig. 6e). 
Fourth, the rate of polyubiquitin disassembly by isopeptidases 
should slow, increasing the half-life of polyubiquitin conjugates 
(Fig. 7). Last, the cleavage of peptide substrates by isopepti-
dases should be inhibited !Fig. 8). Our experiments affirm each 
of these predictions. 
The exact trigger for apoptosis due to proteasome pathway 
inhibition is unknown. However, disruption of proteasome 
pathway function could result in the buildup of detrimental 
proteins (i.e. pro-apoptotic or damaged proteins). Also, as oth-
ers and we have shown, this disruption alters monoubiquitinl 
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polyubiquitin dynamics, which could affect essential processes 
that rely on ubiquitin modification for function. Thus, isopep-
tidase inhibition by aI2-PGJ2 could cause apoptosis by these 
andlor other mechanisms. 
aI2-PGJ2 is the first isopeptidase inhibitor reported to exert 
its effects in intact cells. Nonhydrolyzable ubiquitin dimer an-
alogs (-16 kDa) (38) and ubiquitin aldehyde (-8.5 kDa) (39, 
40) inhibitors are suitable for investigation of isolated ubiq-
uitin isopeptidases, but not for investigations with intact cells. 
We are presently investigating whether a 12-PGJ2 acts directly, 
via Michael adduct formation at their active site sulfhydryl, or 
indirectly by modulating cellular sulfhydryl-disulfide status 
analogous to the mechanism described by Liu et al. (41l. We are 
also investigating whether selective inhibition exists between 
the various isopeptidase family members. 
As a novel modulator of the ubiquitin-dependent proteasome 
pathway, aI2-PGJ2 differs chemically and mechanistically from 
lactacystin (42), eponemycin (43), nitric oxide (44), 4-hydroxynon-
enal (45), and peptide-aldehyde or boronate inhibitors (26), all of 
which slow the disassembly of ubiquitin-protein conjugates by 
irreversibly modifying the 20 S catalytic subunit of the 26 S 
proteasome. The fact that agents as chemically diverse as these 
are each apoptotic agonists reinforces the proposition that the 
ubiquitin-proteasome pathway contains molecular targets for an-
tineoplastic drug development (261. Importantly, our results sug-
gest that inhibition of the isopeptidase component of this path-
way causes apoptosis independently of p53-mediated gene 
transactivation; ~12-PGJ2 inactivated p53-mediated transcrip-
tion, caused apoptosis, and inhibited cellular isopeptidase activ-
ity under identical conditions. Furthermore, it caused apoptosis 
in cells expressing dysfunctional allelic variants of p53 (46, 47). 
Agents that cause apoptosis independently of p53 are of consid-
erable interest, because the majority of drugs used in oncology 
have lower efficacy in cells with mutant p53 compared with cells 
with wild type p53 (48). The response to chemotherapy is com-
plex, and investigations focused on a single genetic factor, like 
p53, may exaggerate its role. However, numerous investigations 
show that disruption of p53 impairs the efficacy of p53-dependent 
drugs, e.g. 5-fluorouracil, used for a range of oncological disorders 
(49-53). 
a 12-PGJ2 can originate from rapid dehydration of its parent 
compound, PGD2 (29, 54). We conclude that the cross-conju-
gated dienone (~9,aI2-0Iefin flanking the e11 carbonyll ac-
counts for the activity we describe. Naturally occurring A series 
PG with a single endocyclic a,{3-unsaturated ketone are not as 
efficacious as apoptotic agonists and isopeptidase inhibitors, 
compared with aI2-PGJ2. It is noteworthy that endogenous 
formation of PGD2 , the parent of a12.PGJ2 , correlates in-
versely with the metastatic potential of murine malignant mel-
anoma cells (55, 56). Although we originally attributed this 
beneficial effect to PGD2 and its inhibition of platelet-tumor 
cell aggregates, it is plausible that aI2-PGJ2 might also have 
contributed as an apoptotic agonist. 
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ABSTRACT 
The tumor suppressor p53 is mutated in more than 50% of all 
cancers. Importantly, most clinically useful antineoplastic 
agents are less potent and efficacious in the context of mutant 
p53. This situation has prompted a search for agents that cause 
tumor cell death via molecular mechanisms independent of 
p53. Our recent investigations with electrophilic prostaglandins 
enabled us to devise a pharmacophore and mechanism of 
action hypothesis relevant to this problem: a cross-conjugated 
a,/3-unsaturated dienone with two sterically accessible electro-
philic /3-carbons is a molecular determinant that confers activity 
among this class of ubiquitin isopeptidases inhibitors, and that 
inhibitors of ubiquitin isopeptidases cause cell death in vitro 
independently of p53. Here, we report the use of the National 
Cancer Institute's Developmental Therapeutics Database to 
identify compounds to test this hypothesiS. Shikoccin (a diter-
Ubiquitin isopeptidases (ubiquitin specific proteases) are a 
family of cysteine proteases that salvage ubiquitin for its 
reuse by the 268 proteasome system (Hochstrasser, 1996; 
Hershko and Ciechanover, 1998) and regulate the activity of 
a variety of substrates by altering their ubiquitination sta-
tus. The ubiquitin salvage activity of the isopeptidases main-
tains a cellular pool of monomeric ubiquitin by cleaving the 
isopeptide bond between the C-terminal carboxyl of ubi quit in 
and the €-amino group of a lysine residue on an adjacent 
protein, thereby disassembling ubiquitin oligomers, ubiq-
uitin-protein conjugates, and ubiquitin-peptide conjugates. 
Few inhibitors of isopeptidases have been identified, other 
than analogs based on ubiquitin itself. These include nonhy-
drolyzable ubiquitin dimer analogs (~16 kDa) (Yin et aI., 
2001) and ubiquitin aldehyde (~8.5 kDa) (Dang et aI., 1998), 
which are suitable for investigating isolated enzymes. Re-
This work was supported by United States Public Health Service grant 
ROl·AI26730. F.A.F. is an investigator of the Huntsman Cancer Institute and 
the Dee Glenn and Ida W. Smith Chair for Cancer Research. 
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pene), dibenzylideneacetone, and curcumin fit the pharma-
cophore hypothesis, inhibit cellular isopeptidases, and cause 
cell death independently of p53 in isogenic pairs of RKO and 
HCT 116 cells with differential p53 status. The sesquiterpene 
achillin and 2,6-diphenyl-4H-thiopyran-4-one, which have 
cross-conjugated die nones with sterically hindered electro-
philic ~-carbons, do not inhibit isopeptidases or cause signifi-
cant cell death. Furthermore, we show that a catalytic-site 
proteasome inhibitor causes cell death independently of p53. 
Combined, these data verify the p53-independence of cell 
death caused by inhibitors of the proteasome pathway and 
support the proposition that the ubiquitin-dependent protea-
some pathway may contain molecular targets suitable for an-
tineoplastic drug discovery. 
cently, we reported that .:l12-prostaglandin J 2 ('~12-PCJ2) is 
a novel isopeptidase inhibitor with activity in intact cells. 
Results with cyclopentenone prostaglandins (PC) prompted 
our hypothesis that isopeptidase inhibition depends on nu· 
ances of olefin-ketone conjugation. For example, .:l12-PCJz, 
with its cross-conjugated a:,/3-unsaturated dienone substitu-
ent and two sterically accessible J3-carbons (Rodriguez et a1., 
1997), was a potent inhibitor of isopeptidase activity. PCA1' 
PCA2, and 15-keto-PCs with a simple a:,f:j-unsaturated ke-
tone and only one accessible J3-carbon were significantly less 
potent. PCB l with an a:,/3-unsaturated ketone and a steri-
cally hindered /3-carbon was inactive (Mullally et al., 2001). 
In its current formulation, our pharmacophore hypothesis 
predicts that compounds chemically unrelated to PC, but 
with a cross-conjugated a:,/3-unsaturated ketone and two 
sterically accessible {i-carbons, will also inhibit ubiquitin 
isopeptidases. Although it disrupts ubiquitin salvage and 
impairs protein turnover, 612-PCJ:z induces apoptosis inde-
pendently of tumor suppressor p53 trans-activation (Mullally 
ABBREVIATIONS: PG, prostaglandin; DBA, dibenzylideneacetone; minimum essential medium; NSC-302979, shlkoccln; 
NSC-156236, achillin; MG115, carbobenzyloxY-L-leucyl-L-leucyl-norvaline; z-llVY -MCA, succinyl-l-Ieucyl-L-Ieucyl-l-valyl-L -tyrosine a-(4-methyl-
coumaryl-7 -amide); z-lRGG-MCA, carbobenzoxY-l-leucyl-l-arginyl-L-glycyl-L-glycine c.-(4-methyl-coumaryl-7 -amide); MTI, (3-(4,S-dlmethyl-
thiazo)-2-yl)-2,S-diphenyltetrazolium bromide; PAGE, polyacrylamide gel electrophoresis; UB, ubiquitin; CHAPS, 3-[(3-cholamidopropyl)dimeth-
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et a1., 2001). Therefore, our corresponding pharmacological 
mechanism hypothesis predicts that such isopeptidase inhib-
itors will also induce cell death independently of tumor sup-
pressor p53 function. Herein, we report the identification of 
dibenzylideneacetone (DBA), curcumin, and, via the National 
Cancer Institute's Developmental Therapeutics Database, a 
diterpene, shikoccin (NSC-302979), as agents that fulfill 
these predictions and reinforce our pharmacophore and 
mechanism hypotheses. As isopeptidase inhibitors, DBA, 
curcumin, and NSC-302979 inhibit the proteasome pathway 
in a manner chemically and mechanistically distinct from 
lactacystin (Fenteany et aI., 1995), eponemycin (Meng et aI., 
1999), and peptide-aldehyde or boronate inhibitors (Adams et 
al., 1999), which all covalently inhibit the 20S catalytic sub-
unit of the proteasome. Our results support the hypothesis 
that the sterically accessible, cross-conjugated O',J3-unsatur-
ated die none is a pharmacophore that confers inhibitory ac-
tivity toward isopeptidases. Furthermore, these results lend 
support to the proposition that the ubiquitin-dependent pro-
teasome pathway contains molecular targets suitable for an-
tineoplastic drug discovery (Kisselev and Goldberg, 2000). 
Experimental Procedures 
Materials. We used ~12-PGJ2 and PGB 1 (Cayman Chemicals, 
Ann Arbor, MIl; dibenzylideneacetone, etoposide, pacJitaxel, Cur-
cumin, and 2,6-diphenyl-4H-thiopyran-4-one (Sigma. St. Louis, MO); 
NSC-302979 and NSC-156236 iDrug Synthesis and Chemistry 
Branch, Developmental Therapeutics Program, Division of Cancer 
Treatment, National Cancer Institute); complete protease inhibitor 
mixture (Roche Applied Science, Indianapolis, IN); enhanced chemi-
luminescence reagents (Amersham Biosciences, Piscataway, NJ); 
antibodies directed against p53 iDO-I), horseradish peroxidase-con· 
jugated secondary antibodies (Santa Cruz Biotechnology. Santa 
Cruz, CAl, and ubiquitin (Zymed Laboratories, Inc., San Francisco, 
CAl; MG115 (Peptides International, Louisville, KY); z·LLVY·MCA, 
z·LRGG-MCA rBiomol Research Laboratories, Plymouth Meeting, 
PAl; (3·(4,5-dimethylthiazo)-2-y\)-2,5.diphenyltelrazolium bromide 
(MTI; Molecular Probes Inc., Eugene, OR); ubiquilin-PEST (Ub· 
PEST; a gift of Dr. Martin Rechsteiner, Department of Biochemistry, 
University of Utah, Salt Lake City, UT). Centricon YM·30 centrifu-
gal filters (Amicon Bioseparations; Millipore, Bedford, MAl. 
Cell Culture. We used RKO and RKO-E6 colon cancer cells (gill 
from Dr. Mark Meuth, Institute for Cancer Studies, University of 
Sheffield, Sheffield, UK). We used HCT 116 colon cancer cells with 
varying degrees of p53 haplosufficiency (gift of Dr. Bert Vogelstein, 
Johns Hopkins School of Medicine, Baltimore. MD!. We maintained 
RKO and RKO-E6 cells in DMEM [supplemented with 2 mM L-
glutamine, 1 mM sodium pyruvate, 50 units/rnl penicillin and strep-
tomycin, and 10% (v/v) fetal bovine serum) in a humidified incubator 
with 5% CO2 , We maintained HCT 116 cells in McCoy's 5A medium 
(supplemented with 1 roM sodium pyruvate, 50 units/ml penicillin 
and streptomycin, and 10% (v/v) fetal bovine serum) in a humidified 
incubator with 5% CO2, 
Immunochemical Detection of Proteins. We removed the me-
dium and lysed cells in 50 mM Tris, pH 7.4, 100 mM NaCl, 2 mM 
EDTA with 0.1% SDS, 0.1% deoxycholate, Ix complete protease 
inhibitor mixture. We measured protein concentration by the method 
of Bradford (l976). We fractionated equal portions of the total cell 
lysate from each sample (12.5 p.g of protein) by SDS-PAGE. We 
transferred proteins to polyvinylidene difluoride blocked with 5% 
(w/v) nonfat dry milk in Tris-buffered saline 120 mM Tris·HCI, pH 
7.5, 100 mM sodium chloride, 0.1% (v/v) Tween 201 We detected 
proteins immunochemically by using primary antibodies directed 
against p53 (1:4000) or ubiquitin (1:1000), followed by horseradish 
peroxidase-conjugated secondary antibodies (1:4000). We detected 
antigen-antibody complexes with enhanced chemiluminescence reo 
agents. We scanned gels and quantified intensities using Kodak ID 
Image Analysis Software (Eastman Kodak, Rochester, NY) 
Cell Viability Assay. We determined cell viability by the MTT 
assay. Briefly, we incubated 1 x 105 cells per well of a sterile, 96-well 
assay plate with 0-60 p.M test compounds for 48 h. We added MTI 
reagent to each well (final concentration, 0.5 mglmlJ and incubated 
for an additional 3 h. We aspirated the media and remaining MTT 
reagent from each well and added 100 p.l of HCVisopropanol (1:24). 
We measured the absorbance of each sample at 405 nm. 
Ubiquitin Isopeptidase Activity Assays. We measured cellular 
isopeptidase enzymatic activity with two assays that used different 
substrates. In one assay we used Ub-PEST, a full.length ubiquitin 
molecule with an 18-amino acid C-terminal peptide extension (total 
mass, 10.5 kDal. Ubiquitin isopeptidases specifically cleave the 18-
amino acid peptide extension, releasing full.length ubiquitin (8.5 
kDa). Briefly, we incubated 6 x 105 cells with 0-60 p.M test COnl-
pounds for 12 h. We lysed cells in 50 p.1 of 25 mM HEPES, 5 mM 
EDTA, 0.1% CHAPS, 5 mM ATP, pH 7.5. We adjusted the protein 
concentration of each sample to 0.3 mglml and incubated with 50 
p.glml Ub-PEST for 45 min at 25°C. Under these conditions Vb·PEST 
hydrolysis occurs at a linear rate. We mixed 20·p,1 samples with 20 p,1 
of2x Laemmli buffer. boiled briefly, and fractionated by SDS-PAGE. 
We monitored isopeptidase activity by determining the amount of 
product (8.5·kDa ubiquitin) formation. 
The second assay used a fluorescent tetrapeptide, z-LRGG·AMC, 
as a substrate that mimics the carboxyl terminus of ubiquitin. 
Isopeptidase activity hydrolyzes the bond between the c-terminal 
glycine and the fluorophore. This tetrapeptide also undergoes slow 
proteolysis by the catalytic subunit of the protellsome. To minimize 
this background rate of proteolysis, we incubated celllysates with 30 
p,M MG1l5 for 30 min at 4 GC, before substrate incubation (>90% 
proteasome inhibition). We treated cells as above, lysed them in 250 
p,1 of lysis buffer per sample, and adjusted their protein concentra-
tion to 05 mg/ml before incubation with MG115. We then added 
z·LRGG-MfC substrate and quantified fluorescence of the M1C 
moiety cleaved by isopeptidase action. 
We determined whether ~12-PGJ2 acted irreversibly. We incu-
bated cell Iysates with vehicle or 100 p.M test compound and mea· 
sured isopeptidase activity fluorometrically. We dialyzed a 500-p.1 
portion of each sample through a Centricon filter with a molecular 
mass cut·off of25 kDa. After washing each sample with 3 volumes of 
assay buffer, we measured the isopeptidase activity in the filtrate. If 
filtration did not reverse inhibition, it implies that ~12-PGJ~ is an 
irreversible inhibitor. 
Statistics. We used analysis of variance for statistical calcula-
tions 
Results 
SubStructure Analysis of the NCI Cancer Screening 
Database. TIle Developmental Therapeutics Program (DTP) 
of the National Cancer Institute (NCI) has systematically 
evaluated >70,000 compounds for cytostatic and cytotoxic 
activity against human cell lines in vitro (Monks et aI., 1997). 
The cell lines typify cancers of the colon, blood (leukemia), 
brain, breast, kidney, lung, ovary, prostate, and skin (mela-
noma). Intramural NCI investigators, who have access to the 
entire database, have applied this information-intensive ap-
proach with promising results (Weinstein et aI., 1997; Shi et 
a1., 1998). Extramural investigators have access to a re-
stricted portion of the database, last released in August 2000. 
Using these available data, we conducted substructure 
searches to test our hypothesis that the cross-conjugated 
O',J3-unsaturated dienone with two sterically accessible J3-car-
bons is the primary molecular determinant that confers the 
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inhibition of isopeptidases. Specifically, we sought nonpros-
tanoid compounds with this feature that varied in the acces-
sibility of their olefinic J3-carbons (e.g., J3-carbons with -R 
versus with -CRa substituents), 
Our substructure query, 2-cyclopenten-5-methylene-l-one 
(Fig. 1, i), yielded eight compounds. All have a cyclic (bis) 
O',J3-unsaturated ketone with one endo- and one exo-olefin. 
They are otherwise chemically unrelated to AI2.PGJ2 or 
other PGs. The NCI provided two of the eight compounds we 
requested for our experimental use: the sesquiterpene NSC-
156236 (Fig. I, ii) and the diterpene NSC-302979 (Fig. 1, v). 
Like AI2-PGJ2 (Fig. I, vi), the endo- and exo-olefins of NSC-
302979 have sterically accessible J3-carbons that can react 
with nucleophiles (e.g., cysteine; Rodriguez et aI., 1997). 
Analogous to PGB1 (Fig. I, iii), NSC-156236 has methyl-
substituted J3.carbons at the endo- and the exo-olefin of the 
dienone. These J3-carbons are sterically hindered and there-
fore should not react readily with relevant physiological nu-
cleophiles (Rodriguez et aI., 1997). To further reinforce our 
pharmacophore hypothesis, we also evaluated several com-
mercially available compounds, Two of these compounds, 
DBA (Fig. 1, vii) and curcumin (Fig. 1, viii), have sterically 
accessible J3-carbons. The final compound, 2,6-diphenyl-4H-
thiopyran-4-one (DPTP; Fig. 1, IV), resembles DBA, except 
that it has a bulky sulfur atom sterically hindering its J3-car-
bons. In summary, our pharmacophore hypothesis predicts 
that compounds ii through iv will be inactive as isopeptidase 
inhibitors and compounds v through viii will be active as 
isopeptidase inhibitors. 
Electrophilic Cross-Conjugated Dienones Inhibit 
Cellular Ubiquitin Isopeptidases. Little is known about 
the substrate specificity of the individual isopeptidase family 
members. To invbstigate total cellular isopeptidase activity, 
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Fig. 1. Chemical structures of the pharmacophore test pane\. We used 
2·cyclopenten·5-methylene-l·one (i) as a substructure to search the NCr· 
DTP database, We identified, and the NCI provided, NSC·156236 (achil· 
lin, ii) and NSC·302979 (shikoccin, v), We also identified and used PGB, 
(iii). DPTP (iv). A12·PGJ2 (vi). DBA (vii). and curcumin (viii) to test our 
pharmacophore hypothesis, 
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which most isopeptidases use as substrates. Figure 2A shows 
the effect of the test panel compounds, .112-PGJ2 (lanes 3-5), 
DBA (lanes 6-8), NSC·302979 (lanes 9-11), PGB 1 (lane 12), 
NSC-156236 (lane 13), curcumin (lanes 15-17), and DPTP 
(lane 18) on cleavage of the lIb-PEST substrate by isopepti-
dases in RCT 116 colon cancer cel! lines. Similar results were 
obtained for RKO cells (raw data not shown). Consistent with 
our pharmacophore hypothesis, the compounds with cross-
conjugated ketones and sterically accessible j3-carbons, .112· 
PGJ2 , DBA, NSC·302979, and curcumin, each inhibited 
isopeptidase activity in a concentration-dependent manner 
(Fig. 2B). Compounds with sterically hindered J3-carbons 
(PGB 1 , NSC-156236, and DPTP) did not inhibit isopeptidase 
activity. The rank order of potency for inhibition of ubiquitin-
PEST hydrolysis by isopeptidases was DBA = NSC-302979 2': 
AI2-PGJ2 > curcumin » NSC-156236 "" PGB1 DPTP. 
To verify the results with lIb-PEST in Fig. 2, z·LRGG-
AMC was used as the substrate for isopeptidases (Fig. ::I). 
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Fig. 2. Effect of the pharmacophore test panel on ubiquitin isopeptidase 
activity in colon cancer cells: Vb·PEST as substrate. A. inhibitlOn of 
isopeptidase proteolysis of Vb·PEST substrate. We treated RKO and 
HCT 116 cells with DMSO vehicle, 6, 20, or 60 J.l.M ':\12-PGJ~, DBA, 
NSC·302979. or curcumin. 60 J.l.M PGB" 60 }J.hl NSC·156236, or 60 J.l.M 
DPTP for 12 h at 37°C. We incubated cell lysates from each treatment 
with Vb·PEST as described under Materials and Methods. We fraction· 
ated samples by SDS·PAGE and detected proteins with ubiquitm 
epitopes immunochemically (HCT 116 ,}, Western blot shown as example 
of raw data), Lane 1 shows the substrate before incubation with lysate. B, 
inhibition of isopeptidase activity by test panel compounds. We deter-
mined isopeptidase activity by measuring, via densitometry. the amount 
ofUb generated by isopeptidase cleavage of Ub·PEST. The amount of Ub 
generated in the vehicle treated sample (A. lane 2) is arbitrarily desig· 
nated 100%. 
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ubiquitin isopeptidase activity, whereas NSC-156236, PGB1 , 
and DPTP did not. The rank-order of potency for inhibition of 
z-LRGG-AMC hydrolysis by ubiquitin isopeptidases was 
NSC-302979 > DBA > tl12-PGJ2 > curcumin » NSC-
156236 "'" PGB1 "'" DPTP. 
Consistent with inhibition of the isopeptidases that disas-
semble ubiquitin polymers and ubiquitin-protein conjugates, 
protein species with polyubiquitin conjugation accumulated 
in cells (e.g., in RKO-E6 cells, Fig. 4A) treated with il12-PGJ2 
(lanes 2-4), NSC-302979 (lanes 5-7), DBA (lanes 8-10) or 
curcumin (lanes 14-16). PGB 1 (lane 11), NSC-156236 (lane 
12), and DPTP (lane 17), compounds that did not inhibit 
isopeptidase activity, did not cause appreciable cellular ac-
cumulation of ubiquitin conjugates. 
As a consequence of polyubiquitin accumulation, monou-
biquitin is initially depleted in cells treated with isopeptidase 
inhibitors [8.5-kDa band, Fig. 4A, lanes 2, 5, 8, and 14 versus 
lanes 1 or 13). We predicted that this would affect the rate at 
which substrates are degraded via the ubiquitin-proteasome 
pathway. RKO and RKO-E6 cells allow a convenient test of 
our pharmacophore hypothesis with p53, a single, explicit 
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Fig. 3. Effect of the pharmacophore test panel on ubiquitin isopeptidase 
activity in colon cancer cells: z-LRGG-AMC as substrate. We treated RKO 
(upper) and HCT 116+'+ cells (lower) with DMSO vehicle, 6. 20, or 60,...M 
<l12-PGJ2 , DBA, NSC-302979. or curcumin. 60 ,...M PGBI' 60 ,...M NSC-
156236, or 60 ,...M DPTP for 12 h at 37·C. We incubated cell lysates (0.5 
mg/mll from each treatment with the isopeptidaee Bubstrate, z-LRGG-
AMC. for 3 h at 37'C. We determined the amount of AMC cleaved by 
isopeptidase fluorometrically, as described under Materials and Methods. 
RKO-E6 cells, an isogenic variant of RKO cells, harbor the 
HPV-E6 oncoprotein that, together with E6-AP ubiquitin 
ligase, hastens proteasome-mediated degradation of p53 
(Fig. 4B, i; Ashcroft and Vousden, 1999). Thus, under most 
conditions, the levels of p53 are significantly lower in 
RKO-E6 cells than in RKO cells (e.g., treatment of cells with 
vehicle or etoposide, a DNA damaging agent; Fig. 4B, ii, lanes 
1 and 2, respectively, and iii). One exception is when the 
ubiquitin-proteasome pathway is inhibited (e.g., treatment of 
cells with the proteasome inhibitor, MG115; lane 3); then, 
accumulation of p53 in RKO-E6 and RKO cells equalizes. 
Accordingly, the ratio of p53 protein (RKO·E6 cellsIRKO 
cells) approached unity in cells treated with the isopeptidase 
inhibitors, ~12-PGJ2 (Jane 4), NSC·302979 (lane 5), DBA 
(lane 6), and curcumin (lane 9). Test compounds that did not 
inhibit ubiquitin isopeptidase activity (PGB 1 (lane 7), NSC 
156236 (lane 8), and DPTP (lane 10)J had p53 protein ratios 
(RKO·E6:RKO) significantly less than unity, suggesting that 
they do not inhibit p53 degradation via the ubiquitin.protea-
some pathway. p53 accumulation caused by the pharmacoph-
ore test compounds is not a result of 20S proteasome inhibi-
tion, because none of the compounds with cross-conjugated 
dienones inhibited the 20S catalytic subunit of the protea-
some under these conditions (Mullally et aI., 2001; and data 
not shown). Note that despite its accumulation in the pres· 
ence of ilI2-PGJz, p53 is inactivated as a transcription factor 
under these conditions (Mullally et aI., 2001); furthermore, 
p53 activation is insufficient to cause its stabilization in 
RKO-E6 cells, because the p53 protein ratio (RKO-E6:RKO =: 
0.1) in etoposide treated cells fails to approach unity. Collec-
tively, the data in Figs. 2 through 4 affirm that our pharma-
cophore hypothesis extends beyond the prostanoid family 
into the diterpene and other chemical families. 
The Prototype Isopeptidase Inhibitor, .112-PGJ2 , In-
hibits Ubiquitin Isopeptidases Irreversibly. Although 
we have not yet identified a covalent complex between an 
isopeptidase and one of the isopeptidase inhibitors, this pro-
posed mechanism of action is consistent with data that we 
have obtained from analyzing cell lysates treated with !l12-
PGJz. Treatment of cell lysates (versus treatment of whole 
cells) should exclude the likelihood of transcriptionaVtrans-
lational events due to the nature of the lysate preparation 
(i.e., sonication of cell lysates probably shears all polynucle-
otidesl. a12-PGJz inhibited isopeptidase activity in treated 
cell Iysates (Fig. 5, predialysis). Furthermore, isopeptidase 
inhibitIOn by tl12-PGJ2 could not be reversed by dialysis of 
treated Iysates (Fig. 5, postdialysis). 
Inhibitors of Ubiquitin Isopeptidases Cause Cell 
Death Independently of Tumor Suppressor p53 Func-
tion. Previously, we showed that electrophilic prostaglan-
dins, typified by ~12·PGJ2' inhibit p53-mediated transcrip-
tion under the same conditions in which they cause cell 
death, suggesting that cell death occurs independently of p53 
(Mullally et aI., 2001). Therefore, integration of our pharma-
cophore and molecular mechanism hypotheses predicts that 
various isopeptidase inhibitors will cause cell death indepen-
dently of tumor suppressor p53 function. Analysis of the NCI 
60 cell line cancer screening data, according to O'Connor et 
al. (997), showed that NCI-302979 and curcumin (NSC-
32982) act independently of p53 (Table n NSC·156236 had 
no appreciable cytotoxic activity. Thus, data on NSC-302979, 
NSC·32892, and NSC-156236, available from the DTP public 
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database, fulfill the minimal, initial prediction of our hypoth-
eses. 
We confirmed that isopeptidase inhibitors caused cell 
death independentlY of p53 by investigating their effects on 
two pairs of isogenic colon cancer cell lines. Isogenic RCT 
116+1+ and RCT 116-1- cell lines have varying degrees of 
p53 haplosufficiency, p53 +1+ and p53 -1-. respectively (Bunz 
et al., 1999). NSC-302979, DBA, C112.PGJ2 , and curcumin 
each caused cell death with equal potency (concentration for 
half-maximal effect) and efficacy (maximal effect) in RCT 
116+1+ cells that are homozygous for p53 and RCT 116~/­
cells that are null for p53 (Fig. 6, right hand). NSC-156236, 
PGBl' and DPTP, which did not inhibit ubiquitin isopepti· 
dase activity at concentrations <60 p.M did not cause signif· 
icant cell death in RCT 116+1+ or RCT 116-1- cells. Isogenic 
RKO and RKO-E6 cells accumulate p53 to varying degrees 
after genomic stress due to the enhancement of p53 ubiquiti-
nation by RPV·E6. NSC·302979, DBA, C112-PGJ2 , and cur-
cumin each caused cell death with equal potency and efficacy 
in RKO and RKO·E6 cells (Fig. 6, left). NSC-156236 PGB 1, 
and DPTP did not cause significant cell death in RKO Oi 
RKO-E6 cells. 
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etoposide and paclitaxel on these same pairs of cells. Etopo-
side typifies agents that cause cell death via a p53-dependent 
pathway (Lowe et al., 1993). Accordingly, its potency in RCT 
116-/~ cells was -4-fold less than its potency in RCT 
116+1+ cells (Fig. 7, top right). Similarly, etoposide potency in 
RKO·E6 cells was -3-fold less than its potency in RKO cells 
(Fig. 7, top left). Paclitaxel typifies an agent that causes cell 
death via a p53-independent pathway (O'Connor et aI., 1997). 
Although its efficacy (maximal effect observed) in the RCT 
116-1- and RKO·E6 cells with dysfunctional p53 exceeded its 
efficacy in the corresponding RCT 116+1+ and RKO cells, the 
potency of paclitaxel (concentration for half· maximal effect) 
was equivalent in RCT 116-1- compared with RCT 116+1+ 
cells, as well as in RKO-E6 compared with RKO cells (Fig. 7, 
middle). Lastly, we evaluated MG 115, an inhibitor of the 20S 
catalytic subunit of the proteasome, to compare its effects 
with isopeptidase inhibitors. There are conflicting reports on 
the role of p53 in cell death caused by proteasome inhibitors 
like MG115 (Dietrich et al., 1996; Shinohara et al., 1996; 
Lopes et al., 1997; Adams et al., 1999; Wagenknecht et a1., 
1999; An et al., 2000). MG115 caused cell death with equal 
potency and efficacy in RCT 116+1+ cells versus RCT 116-1-
and in RKO·E6 cells versus RKO cells, analogous to isopep-
250 kDa 
100 kDa 
8.5 kDa _____ ---J 
Fig. 4. Effect of the pharmacophore test 
panel on ubiquitin-dependent proteolysis 
in colon cancer cells. A, accumulation of 
polyubiquitin. We treated RKO·E6 cells 
with DMSO vehicle for 24 h. 37°C. or with 
the concentratlOns of test compounds that 
gave 80% cell death (as determined by cell 
viability assay at 48 h) for 6, 12. or 24 h at 
37°C IEC.o •. :U2·PGJ, (13.2 1J.;.\1l. DBA 
(12.0 I-'M), NSC-302979 (3.5 I-'M). or cur· 
cumin (17 MM)J. For compounds that were 
inactive in the cell viability assay. we 
treated with the highest concentrations 
examined (60 ",M PGB,. N8C·156236, 
and DPTP for 24 h at 37·C). We fraction· 
ated cell lysates by 8DS-PAGE and de-
tected proteins with ubiquitin epitopes 
immunochemically. B, accumulatlOn of 
p53, a protein targeted for proteasomal 
degradation. i. Schematic depicting p53 
degradation via the proteasome pathway 
in RKO cells versus RKO-E6 cells. The 
activity of the HPV E6 oncoprotein has-
tens p53 degradation in RKO-E6 cells. ii, 
We treated RKO and RKO-E6 ceJls with 
vehicle, etoposide (50 ",M), MG1l5 /20 
ILM). ~12-PGJ2 (60 1-'}.1), NSC-302979 (20 
1-'11-1). DBA (20 I-'M), PGB. (60 ",M), NSC· 
156236 (60 ",Ml. curcumin (60 ILM). or 
DPl'P (60 MM) for 6 h. 37°C. We fraction· 
ated lysates by SDS·PAGE and deter· 
mined their p53 content immunochemi· 
cally. iii, We measured p53 levels by 
densitometrv and calculated the ratio of 
p53 protein 'in RKO·E6 cellslRKO cells. 
Lane 2 3 4 5 6 7 8 9 10 11 
B 
RKO E1/E2JE3 
p53 ~UblqulUn 26S 
k1 ~ Proteasome p53 
X PoIYUb-JJ53 III Degradation ~ k3 RKo-E6 HPV·E6 I I 
p53 + Ublqultln k2 » k1 
i. 
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tidase inhibitors (Fig. 7, bottom). Table 2 summarizes the 
poteney of all compounds as cell death agonists in both pairs 
of cell lines. 
Discussion 
Our results indicate that nonprostanoid classes of com-
pounds, with a,l3-unsaturated ketones and two sterically ac-
cessible l3-carbons, will inhibit ubiquitin isopeptidase activo 
ity. We further demonstrate that these compounds cause cell 
death independently of p53 tumor suppressor function in 
vitro. Specifically, the diterpene NSC-302979, the synthetic 
compound DBA, the prostaglandin .:H2-PGJ 2' and the cur-
cuminoid curcumin all cause cell death with efficacy and 
potency that is indistinguishable (p > 0.05) between HCT 
116 p53-
'
+ and HCT 116 p53-' - or RKO and RKO·E6 cells. 
Furthermore, cell death correlated with inhibition of isopep-
tidase activity. Regression analysis (lCso for inhibition of 
z-LRGG-AMC hydrolysis by isopeptidase versus lCso for cy-
totoxicity) yields a straight line with a correlation coefficient 
r = 0.93 (n 7). Regression analysis (ICso for inhibition of 
ubiquitin.PEST hydrolysis by isopeptidase versus lC50 for 
cytotoxicity) also yields a straight line with r == 0.73 (n 
13). 
Inhibition of ubi quit in isopeptidase activity probably prop-
agates cell death by shifting the polyubiquitin chain length 
equilibrium to one of greater molecular mass. As a conse-
quence of unfettered polyubiquitin chain grov.'th, the pool of 
DMSO ~12-PGJ2 DMSO ~ 12.PGJ2 
Fig. 5. Reversibility of isopeptidase inhibition by .:l12-PGJ2, We treated 
celllysates (0.5 mg/mD with DMSO vehicle or 100 ~ ~12-PGJ2 for 1 h 
at 25·C. We divided each of the treated lysates into two aliquots. We 
immediately analyzed one aliquot for isopeptidase activity by incubating 
with z-LRGG-AMC as described previously (PreDialysisl. We dialyzed 
the second aliquot by washing with 3 volumes of a.ssay buffer on a 
centricon YM·30 column, followed by analysis for isopeptidase activity by 
incubating with z·LRGG·AMC (PostDialysisl. 
TABLE 1 
Mean LCa!) of NCI DTP database compounds examined 
Mean LCso 
Compound 
NSC-302979 5.4:!: 106" 




6.6 :!: 105• Indistinguishable (p 0.05) 
6.8 :!: 10" Indistinguishable (p » 0.05) 
Inactive 
• Results from 18 cell lines with wild-type p53 
b Results from 41 to 42 eelllines with mutant/deleted p53. 
monoubiquitin diminishes. Alteration of monoubiquitinl 
polyubiquitin dynamics inevitably affects several transcrip-
tion factors other than p53 (Desterro et a1., 2000). Further-
more, with depleted monoubiquitin pools, cells are hampered 
in their efforts to rid themselves of damaged/toxic proteins, 
eventually affecting protein-protein or protein·DNA interac-
tions that modulate cell survival and apoptosis. Although our 
data support a covalent mechanism, we are presently inves-
tigatingwhether a,l3-unsaturated dienones covalently inhibit 
isopeptidases, specifically, via their electrophilic l3-carbons 
iI tJ)Ot t) I' ~~,.3r-'-I-4~~,\ ~~ 








Fig. 6. Cytotoxicity of the pharmacophore test panel in HCT 116 and 
RKO cell lines with different p53 status. We mcubated RKO and RKO·E6 
cells (left column.!. and HCT1l6 p53 +1. and HCT116 p53 1 cells (right 
column) with vehl(~le or 0.5-60 p.M NSC.302979, DBA. A12-PGJ~. NSC-
156236, PGBI' curcumin, or DPTP for 48 h at 37·C. We measured cell 
viability with MTT reagent as described under Materials and Methods . 
Data are percentage of control viability, mean S.D. (n 4). 
60 
(e.g., Michael adduct formation between an isopeptidase cys-
teine residue and the ,a-carbon of a dienone). Note that com-
pounds with sterically inaccessible or inert ,a-carbons (NSC-
156236, PGBv and DPTP) were inactive as isopeptidase 
inhibitors. 
We used the substructure search capabilities of the NCI 
DTP database (60 cell-line screen) to identify NSC-302979 
and NSC-156236, compounds used to test our pharmacoph-
ore and mechanism of action hypotheses. We think our re-
sults, along with the results by NCr scientists (O'Connor et 
aI., 1997; Weinstein et al., 1997; Shi et aI., 1998), exemplify 
the potential of this database and compound repository and 
the foresight of the NCr Developmental Therapeutics 
Branch. Others have suggested that the database content is 
misaligned with the goal to discover new anticancer drugs, 
based on a poor correlation between clonogenic survival and 
the NCI archival antiproliferative activity (Brown, 1997). 
However, direct extension of data acquired in vitro to clinical 
situations in vivo is rarely straightforward. Used prudentlY, 
to enable or to advance mechanistic and pharmacophore hy-
RKO HCT116 p53 +1+ 
RKO.E6 HCT116 p53 . 1-
'- ~'i . :~ • l"1~i 
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Fig. 7. Cytotoxicity of the calibration set in HCT 116 and RKO cell lines 
with different p53 status. We incubated RKO and RKO-E6 cells (left 
column), and HCT1l6 p53 ,I. and HCT1l6 p53 f cells (right column I 
with vehicle, 0.01 to 100 J.Lhl etoposide. 0.001 to 1 1".11 paclitaxel, or 0.02 
to 2 J.Lhl MG1l5 for 48 h at 37·C and determined their effect on cell 
viability, as described under Materials and Methods. 
TABLE 2 
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potheses, the database supports the quest for anticancer 
drugs with novel structures and mechanisms of action. 
Our mechanistic and pharmacophore hypotheses are com-
patible with the structure-activity relationships reported by 
Kato et ai. (1986), Sasaki et al. (1991) and Sasaki and Fuku-
shima (1994). Kato et ai. (1986) reported that ..l12-PGJ2 and 
several related ..17 -PGA I derivatives (all of which are cross-
conjugated dienones) increased the life span of Ehrlich as-
cites tumor-bearing mice: i.p. doses of 20 to 30 mglkg/day for 
5 consecutive days prolonged survival 66 to 111 ~. In addi-
tion, both ..112-PGJ2 and ..17-PGA1 exhibit little cross-resis-
tance with cisplatin and doxorubicin in vivo (Sasaki et aL, 
1991; Sasaki and Fukushima,1994). Despite these promising 
results, D.7-PGA j is rapidly metabolized to an inactive com-
pound (t 1I2 < 5 min) in serum (Suzuki et a1., 1998) Therefore, 
our discovery of isopeptidase inhibitors among chemical 
classes other than PG might be advantageous in surmount-
ing any difficulties intrinsic to the antineoplastic develop-
ment of the PG class. 
There exists considerable debate as to whether agents that 
inhibit the proteasome pathway cause cell death via a p53-
independent process (Dietrich et aI., 1996; Shinohara et aI., 
1996; Lopes et aI., 1997; Adams et aL, 1999; Wagenknecht et 
aI., 1999; An et aL, 2000). Our results with inhibitors of 
ubiquitin isopeptidase activity and with a representatIve cat-
alytic subunit inhibitor of the 20S proteasome accord with 
those who conclude that proteasome inhibition causes apo-
ptosis independently of p53. This debate may originate from 
faulty assumptions about the competence of p53 that accu-
mulates in cells treated with proteasome pathway inhibitors. 
For instance, genetically wild-type p53 accumulates in the 
presence of the isopeptidase inhibitor D.12-PGJ 2 , but in a 
conformationally and functionally impaired state (Moos et 
aI., 2000; Mullally et aL, 20011. An et aL (2000) have also 
reported that accumulation of wild-type p53 protein and in-
duction of apoptosis occur as independent markers of protea-
some inhibition. Therefore, one must use caution when in-
terpreting the consequences of p53 accumulation without 
first testing its functionality . 
The response to chemotherapy is complex; focus on a single 
factor, no matter how prominent, may exaggerate its role. 
However, numerous investigations show that disruption of 
p53 impairs the potency and efficacy of drugs used in oncol-
ogy [e.g., 5-fluorouracil (Lowe et aI., 1994, 1995; Mueller and 
Eppenberger, 1996; O'Connor et aI., 1997; Bunz et aI., 1999; 
Pich, 1998; Weller, 1998; Karpf et aI., 2001)]. It is notable 
that vinca alkaloids, one of the few drug classes that act 
panel and calibration compounds in HCT 116 and RKO cells with different p53 status 
Compound RKO RKO-E6 
NSC-302979 1.8:': 0.1 1.4 0.1 
DBA 7.0:': 0.6 6.5 :': 1.1 
il12·PGJ2 9.0:': 0.8 9.2:': 1.0 
Curcumin 12.5 5.9 14.9 8.5 
NSC-156236 >60 >60 
PGB) >60 >60 
DPl'P >60 >60 
Etoposide 7.3 1.6 20.0 2.7 
Paclitaxel 0.004:': 0.0 0.004::: 0.0 
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independently ofp53 (O'Connor et aI., 1997; Fan et aI., 1998), 
may target the proteasome in addition to tubulin (Piccinini et 
aI., 2001). LDP-341, the first proteasome inhibitor to enter 
clinical trials, seems to have a favorable safety and efficacy 
profile (Dalton et aI., 2001). Clinical studies to evaluate pro-
teasome inhibition as an adjuvant to systemic chemotherapy 
are also currently in development (Cusack et aI., 2001). Our 
results demonstrate that another component of the protea-
some pathway, isopeptidase activity, warrants further inves-
tigation as a target for antineoplastic drug discovery. 
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UNPUBLISHED RESULTS AND FUTURE DIRECTIONS 
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4.1. Unpublished Results 
I have provided evidence supporting our hypothesis that certain 
electrophilic prostaglandins inhibit the ubiquitin-specific protease (USP) activity 
of the proteasome pathway. Furthermore. I have shown that the cross-conjugated 
a,~-unsaturated dienone is a molecular determinant for the potency of this 
activity, and that this chemical feature causes an alteration in cellular ubiquitin 
dynamics, resulting in accumulation of the polyubiquitin pool. decrease in the 
monoubiquitin pool, and decrease in the degradation rate of a specific proteasome 
substrate, p53. In this chapter, using the model isopeptidase inhibitor, ~12-PGJ2, 
additional mechanistic evidence will be provided that supports our hypothesis that 
isopeptidase inhibition by cross-conjugated a,~-unsaturated die nones proceeds 
via a covalent interaction, and that it is the subsequent inhibition of global cellular 
protein degradation that ultimately causes cell death. Lastly, in section 4.2, I will 
discuss some of the future directions that our findings suggest may yield valuable 
data with regard to proteasome pathway-induced cell death and chronic 
inflammatory diseases. 
4.1.1. ~12-PGh Does Not Cause Polyubiquitin Accumulation 
via PPARy Activation 
PGs of the J-series, in particular 15-deoxy-~12,~14-PGh (l5d-PGh), 
activate the nuclear hormone receptor peroxisome proliferator-activated receptor, 
isoform gamma (PPARy, discussed in greater detail in Chapter 5) 1.2, Until 
recently, this was the only known receptor for cyclopentenone PGs, resulting in 
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many proposals that attempted to associate PPARy with the other major properties 
of cyclopentenone PGs, cell cycle arrest and apoptosis 3-6. Though ~ 12-PGJ~ is a 
much lower affinity agonist for PPARy than 15d-PGJ2, and though PPARy has 
never been associated with regulating any component of the proteasome pathway, 
we wanted to rule out the possibility that PPARy activation by ~12-PGJ2 was the 
nlechanism by which polyubiquitin was accumulating in cells. Data presented 
here denl0nstrate that the high affinity synthetic PPARy agonist, troglitazone, 
which does not possess an a,~-unsaturated dienone, does no~ cause the 
accumulation of polyubiquitin in treated cells [Figure 4.1, lanes 2 - 7 vs. lane 1]. 
Under the same conditions, ~12-PGJ2 causes polyubiquitin accumulation, even at 
20 11M [Figure 4.1, lane 8 vs. lane 1], a ten-fold lower concentration than 
troglitazone (200 11M). 
Furthermore, the effects of PPARy activation are mediated via gene 
activation, yet ~12-PGJ2 inhibits isopeptidase activity in whole celllysates at 
concentrations sinlilar to those seen in intact cells [Figure 4.2]. These whole cell 
lysates were sonicated during preparation, a process likely to result in the 
shearing, and thus inactivation, of all DNA and RN A. Therefore, these data 
suggest that the mechanism by which ~12-PGh causes polyubiquitin 
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Figure 4.1. Effect of a PPARy Agonist on Polyubiguitin Accumulation. RKO cells 
were treated with DMSO, the PPARy agonist, troglitazone (5 200 j.lM), or ~12-
PGJ2 (20 j.lM) for 6 hours. Cell lysate proteins were separated by polyacrylamide-
gel electrophoresis, transferred to a PVDF membrane, and analyzed 
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Figure 4.2. Effect of Cyclopentenone PGs on Isopeptidase Activity In Vitro. RKO 
celllysates were treated with DMSO or 6 - 360 j..tM of PGA, or i112-PGh for 1 
hour. Lysates were incubated with Db-Pest, boiled in SDS loading buffer to stop 
the reaction, separated by polyacrylamide-gel electrophoresis, transferred to a 
PVDF membrane, and analyzed immunochemically with an antibody to ubiquitin 
to determine relative amounts of product formation (monoubiquitin). 
Monoubiquitin product was quantitated by densitometry and is represented as 
percent of control. Inset indicates EDso Cj..tM). 
4.1.2. Ll12-PGJ2 Does Not Cause Polyubiquitin Accumulation via 
Formation of Reactive Oxygen Species 
68 
Recent work demonstrated that cyclopentenone PGs cause the production 
of reactive oxygen species (ROS) in treated cells 7. The authors claim that the 
increase in ROS caused polyubiquitin accumulation (via increased protein 
oxidation) and cell death, and that co-treatment with the antioxidant, a-
tocopherol, reversed these phenotypes. However, they did not show data 
demonstrating a reversal of polyubiquitin accumulation. Therefore, I set forth to 
determine if generation of ROS played a role in the accumulation of polyubiquitin 
in Ll12-PGJ2 treated cells. RKO cells were treated with either Ll12-PGh alone or in 
combination with a-tocopherol. No difference was observed in the accumulation 
of polyubiquitin with a-tocopherol co-treatment [Figure 4.3, lanes 2 and 3 vs. 
lane 1 and lanes 5 and 6 vs. lane 4], suggesting that ROS do not playa significant 
role in the accumulation of polyubiquitin in treated cells. I also did not observe 
any apparent effect of a-tocopherol co-treatment with regard to cell death (data 
not shown). However, it must be noted that the previous study was performed in a 
different cell type (neuronal cells), therefore, I cannot rule out the possibility that 
ROS generation plays a role in polyubiquitin formation in that model system, 
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Figure 4.3. Effect of an Antioxidant on Polyubiguitin Accumulation. RKO cells 
were treated with 20 - 60 J,lM ~12-PGJ2 and 0 50 J,lM of the antioxidant. u-
tocopherol, for 6 hours. Cell lysate proteins were separated by polyacrylamide-gel 
electrophoresis, transferred to a PVDF membrane, and analyzed 
immunochemically with an antibody to ubiquitin to determine relative amounts of 
polyubiquitin. 
4.1.3. ~12-PGJ2 Inhibits Isopeptidase Activity 
Via a Covalent Mechanism 
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As the data in Figure 4.2 demonstrate, ~12-PGJ2, and to a lesser extent 
PGA,. inhibit isopeptidase activity in sonicated celllysates. Not only does this 
data strongly suggest that PPARy plays a negligible role in polyubiquitin 
accumulation in treated cells, but, through the same reasoning, it suggests that no 
other transcriptional/translational mechanism plays a significant role in this 
phenotype. Furthermore, the data in Chapter 3, Figure 5, demonstrate that the 
inhibition of isopeptidase activity in treated lysates is, in the least, a high affinity 
binding reaction, as this inhibition cannot be reversed by dialysis. Combined, 
these data open up the possibility of a direct inactivation of isopeptidase(s) by 
~12-PGJ2 in cells, consistent with cellular polyubiquitin accumulation. However, 
celllysates are a heterogeneous mixture of cellular components, and therefore 
these data do not rule out the possibility that other isopeptidase regulatory 
components are the actual target(s) of ~12-PGJ2. Therefore I set out to determine 
if ~12-PGJ2 could inhibit the activity of a purified model isopeptidase. 
Our data show that ~12-PGJ2 inhibits the activity of purified UCH-L3, 
consistent with direct inhibition of this isopeptidase [Figure 4.4]. It is noted that 
an exceptionally high concentration of ~12-PGJ2 (600 JlM) is needed to achieve 
inhibition. However, this reaction is carried out in 10 mM DTT, which may 
effectively compete for accessible isopeptidase thiols. Also, this reaction was 
carried out at 4°C, which may result in slowing the rate of reversibility between 
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Figure 4.4. Effect of tl12-PGJ2 On Ubiquitin C-Terminal Hydrolase Activity III 
Vitro. DCH-L3 was incubated with DMSO or 600 J.!M tl12-PGJ2 for 3 hours at 4 
°C, then incubated with Db-Pest for 2 - 8 hours at 25°C. The reaction was 
terminated by boiling in SDS loading buffer, and isopeptidase activity was 
determined as before. Monoubiquitin product was quantitated by densitometry 
and is represented as arbitrary units. 
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cellular target of 812-PGJ2, therefore it may represent a low affinity target. These 
data, however, are consistent with covalent modification of isopeptidases, in vitro, 
suggesting that this mechanism may playa role in the inactivation of cellular 
isopeptidases, in vivo. 
4.1.4. 812-PGJ2 Causes Cell Death Via Inhibition of Global 
Cellular Protein Degradation 
Cyclopentenone PGs are reactive molecules and are known to covalently 
modify multiple cellular proteins 8.9. It is possible that other cellular targets, 
instead of isopeptidases, playa dominant role in the cytotoxicity of these 
compounds. I therefore set out to detemline if isopeptidase inhibition is the 
prominent mechanism by which the model isopeptidase inhibitor, 812-PGJ 2, 
causes ~ell death. However, I have yet to determine the 812-PGJ2-targeted 
isopeptidase(s) that is/are critical for maintaining proper cellular ubiquitin 
dynamics, so cellular 'rescue' experiments could not be performed by over-
expressing any given isopeptidase. Instead I chose to manipulate a pathway we 
predict to be intricately linked with the isopeptidase inhibitor's mechanism of 
action, protein synthesis. My hypothesis, that 812-PGJ2 inhibits ubiquitin 
isopeptidase activity, predicts that 812-PGJ 2 indirectly prevents proteasomal 
degradation, resulting in the inhibition of global cellular protein degradation. If 
inhibiting proteasomal degradation is what is causing cell death by 812-PGJ2, 
then inhibiting protein synthesis should have a rescue effect on cells. This has in 
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Figure 4.5. Effect of Proteasome and Isopeptidase Inhibitors on Global Protein 
Degradation. RKO cells were metabolically labeled with 35S-methionine for 2 
hours (pulse), then treated with DMSO, 20 MM MG 115, or 60 MM i112-PGJ 2 for 2 
hours in the absence of 35S-methionine (chase). Celllysates were subjected to 
trichloroacetic acid precipitation, separated into pellet (intact proteins) and 
supernatant (digested proteins), and quantitated by scintillation to determine the 
percentage of proteolysis (supernatant counts as a percent of total counts). Data 
are percent of control and are shown as the mean +/- S.D., 11 = 3 experiments, 
with statistical significance indicated (*, ANOV A, P <0.05). 
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(CHX) 10, however no explanation was given for this effect. If, as expected. CHX 
rescue is simply due to preventing the buildup of toxic levels of cellular proteins 
in the context of an inhibited ubiquitin-proteasome pathway, then rescue of 
polyubiquitin dynamics should accompany rescue from cell death by ~12-PGJ2. 
First, I demonstrate that, similar to a catalytic-site inhibitor of the 
proteasome (MG 115), inhibition of the ubiquitin-proteasome pathway by il12-
PGh translates into inhibition of total cellular protein degradation [Figure 4.5]. 
Also, I show that both il12-PGh and MG 115 cause cell death and, as expected, 
that co-treatment of cells with CHX prevents cell death under the same conditions 
[Figure 4.6]. It is unlikely that rescue from cell death is due significantly to cell 
cycle arrest caused by CHX, as this experiment is relatively short (7 hours). 
Furthermore, in agreement with the prediction that CHX's rescue effects have to 
do with restoring cellular protein homeostasis (i.e., protein synthesis == protein 
degradation), CHX partially rescues the polyubiquitin accumulation and 
monoubiquitin depletion phenotypes in cells treated with 20 ~M [Figure 4.7, lane 
2 vs. lane 4] or 60 ~M il12-PGh [Figure 4.7, lane 3 vs. lane 5]. Though MG 115 
does not cause polyubiquitin to accumulate under these conditions, therefore not 
allowing the observation of polyubiquitin rescue, the rescue effect is seen with 
regard to the depletion of monoubiquitin [Figure 4.7, lanes 6 and 7 vs. lanes 8 and 
9]. Although not a definitive proof, these data are consistent with the hypothesis 
that cyclopentenone isopeptidase inhibitors cause cell death primarily by 
inhibiting cellular protein degradation. 
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Figure 4.6. Effect of Protein Synthesis Inhibition on Cell Death Caused by 
Proteasome and Isopeptidase Inhibitors. RKO cells were treated with DMSO, 20 
JlM MG 115, or 60 JlM ~12-PGh for 7 hours, +/- 10 Jlg/mL cycloheximide. Cells 
were trypsinized and stained with trypan blue to determine the number of non-
viable cells. Data are percent of control and are shown as the mean +/- S.D., 11 = 3 
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Figure 4.7. Effect of Protein Synthesis Inhibition on Polyubiquitin Dynamics. 
RKO cells were treated with DMSO, 6 ~M to 20 ~M MG 115, or 20 ~M to 60 
76 
~M ~12-PGJ2 for 7 hours, +/- 10 ~g/n1L cycloheximide. Cell lysate proteins were 
separated by polyacrylamide-gel electrophoresis, transferred to a PYDF 
membrane. and analyzed immunochemically with an antibody to ubiquitin to 
determine relative amounts of mono- and polyubiquitin. 
4.2. Future Directions 
4.2.1. Determine if Cell Death Proceeds Via ER-Stress Induced 
Acti vation of Caspase-12 
77 
One aspect of proteasome pathway that I am currently pursuing is with 
regard to how cells attempt to respond to toxic quantities of proteins and how this 
response can lead to cell death caused by proteasome pathway inhibitors. Others 
and I have observed that cyclopentenone PGs and catalytic-site proteasome 
inhibitors up-regulate cytosolic heat shock proteins, such as HSP70 [Figure 4.8, 
panel A.] 11-13. Cyclopentenone PGs and catalytic-site proteasome inhibitors also 
up-regulate the resident heat shock protein of the endoplasmic reticulum (ER), 
GRP78 [Figure 4.8, panel B.] 13.14. I have also observed that isopeptidase and 
proteasome inhibitors cause ER proliferation (data not shown), a sign that the ER 
is trying to cope with a large quantity of unfolded proteins. These results suggest 
that both of these types of proteasome pathway inhibitors cause the activation of 
the unfolded-protein response (UPR) of the ER. Cell death mediated via the UPR 
occurs by a novel apoptotic mechanism, only recently identified: activation of 
ER-specific caspase-12. The only identified activation of this caspase occurs due 
to ER stress; it then goes on to activate effector caspases, caspase-9 and caspase-
3 15. Therefore, it will be interesting to determine if these proteasome pathway 
inhibitors activate caspase-12. Furthermore, it will be interesting to determine if 
inhibitors of heat shock proteins (e.g., the HSP90 inhibitor, geldanamycin) 
exacerbate cell death, and conversely, if promoters of protein re-folding (e.g., 
"chemical chaperones") rescue cells from cell death. 
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Figure 4.8. Effect of Proteasome and Isopeptidase Inhibitors On The Unfolded 
Protein Response. RKO cells were treated with DMSO, 20 JlM MG 115, or 60 
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JlM il12-PGh for 6 hours. Cell lysate proteins were separated by polyacrylamide-
gel electrophoresis, transferred to a PYDP membrane. and analyzed 
immunochemically with an antibodies to HSP70 (an inducible cytosolic heat 
shock protein), A., or GRP78 (BiP; an inducible ER heat shock protein), B. 
Protein bands were quantitated by densitometry to show the increase in HSP70 or 
GRP78, relative to control. 
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Figure 4.9. Effect of Proteasome and Isopeptidase Inhibitors on the Quantity of 
Cellular Lysosomes. RKO cells were incubated with DMSO, A., 20 f.lM MG 115, 
B., or 60 f.lM ilI2-PGJz, C., for 4 hours. To detect cellular lysosomes and nuclei, 
cells were stained with 50 nM LysoTrackerTM Red DND-99 and DNA was stained 
with 100 nM Hoechst 33342. 
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Parallel to the ERiUPR observation, I have made the novel discovery that 
in cells in which the ubiquitin-proteasome pathway is inhibited, a compensatory 
increase in the number and/or size of acidic lysosomes occurs [Figure 4.9, panels 
B. and C. vs. A.; L112-PGh, MGl1S, and DMSO, respectively]. This suggests that 
the cells are attempting to by-pass the proteasome pathway by activating alternate 
protein degradation pathways. This is interesting because knowing the pathways 
that lead to cell death may lead to effective combination therapies for PS-341, and 
may also aid in the early identification of patient populations that will be 
nonresponders. 
4.2.2. Determine if Ubiquitin-like Isopeptidases 
are Inhibited by L112-PGh 
Other future work will include determining if other types of isopeptidases 
are inhibited by cyclopentenone PGs. There are approximately 11 ubiquitin-like 
molecules in eukaryotes that are used to covalently modify proteins in a manner 
analogous to ubiquitin (i.e., an isopeptide bond between the C-terminus of the 
ubiquitin-like monomer and a protein substrate lysine) 16.17. Less is known about 
these modifications than about ubiquitination; however, it appears that most of 
them are used as monomers, and that none of them are used as targeting 
mechanisms for proteasomal degradation. In fact, some of these modifications are 
believed to antagonize ubiquitination by occupying lysine residues needed for 
polyubiquitin conjugation 18. Interesting preliminary data suggest that de-
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Figure 4.10. Effect of Cyclopentenone PGs on Sumo-l Accumulation. RKO cells 
were treated with DMSO or 20 ).lM to 60 ).lM PGA2 or 612-PGJ:c for 6 hours. Cell 
lysate proteins were separated by polyacrylamide-gel electrophoresis, transferred 
to a PVDF membrane, and analyzed immunochemically with an antibody to 
Sumo-I. 
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cyc1opentenone PGs [Figure 4.10., lanes 2 - 5 vs. lane 1]. What is of further 
interest is that, unlike with polyubiquitin accumulation, PGA 1 appears effective at 
causing the accumulation of high molecular weight sumoylated proteins under 
conditions in which polyubiquitin does not accumulate. While these PGs have 
differences in potency with regard to cell death and proteasome pathway 
inhibition, they have similar potency with regard to the inhibition of several 
transcription factors, such as p53 19. It is believed that p53 levels are regulated by 
sumoylation, therefore it will be interesting to determine if Sumo-l plays a role 
with regard to cyclopentenone PG-mediated inactivation of p53 and/or other 
transcription factors. 
4.2.3. Identify Isopeptidase(s) Inhibited by 812-PGJ2 
An obvious future direction is to attempt to identify the isopeptidase(s) 
that PGs inhibit. Over-expressing this enzyme in cells would allow for more 
meaningful 'rescue' experiments to be performed, and more detailed mechanism 
of action data to be collected. Furthermore, identification would be a first step in 
the synthesis of specific inhibitors to isopeptidases, which may have more 
favorable pharmacological profiles in model organisms than 812-PGh. 
4.2.4. Model Chronic Inflammation with Low Concentrations of 
812-PGJ2 to Determine Long-term Effects 
Lastly, it would be interesting to determine to what degree chronic 
inflammation plays a role in altering the kinetics of the proteasome pathway. 
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Although most of this work has centered around relatively high concentrations of 
PGs for short time periods (e.g., 60 J.lM of ~12-PGJ2 for:5 12 hours; Chapter 2. 
Figure 5), I have observed that at lower concentrations for longer time periods 
(e.g., 6 J.lM of ~12-PGJ2 for::; 24 hours; Chapter 3, Figure 4), polyubiquitin 
accumulates. This is interesting because it takes -3 weeks for colon cells to 
migrate from the base of the colon crypt to the top, where they are sloughed off. 
The longest of the experiments in this work was 48 hours, so since pharmacology 
is a function of time and concentration, it will be interesting to see what effect 
long-term treatment with very low concentrations of PGs will have on proteasome 
pathway inhibition. 
4.3. Materials and Methods 
4.3.1. Materials 
I used ~12-PGJ2 and PGA 1 (Cayman Chemicals, Ann Arbor, MI); MG115 
(Peptides International, Louisville, KY); Troglitazone and UCH-L3 (Biomol, 
Plymouth Meeting, PA); a-tocopherol, cycloheximide, trichloroacetic acid, and 
chloroquine (Sigma-Aldrich, St. Louis, MO); EasyTag 35-S Protein Labeling Mix 
(NEN Life Sciences, Boston, MA); try pan blue (Invitrogen Corporation. 
Carlsbad, CA); LysoTrackerTM Red DND-99, SlowFade® Light Antifade Kit, and 
Hoechst 33342 (Molecular Probes, Eugene, OR); complete protease inhibitor 
mixture (Roche Molecular Biochemicals, Indianapolis, IN); enhanced 
chemiluminescence reagents (Amersham Pharn1acia, Piscataway, NJ); antibodies 
directed against ubiquitin and Sumo-1 (Zymed Laboratories, Inc., San Francisco, 
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CA), GRP78 (BD Biosciences, San Jose, CA), HSP70 (Stressgen 
Biotechnologies, Inc., San Diego, CA), horseradish peroxidase-conjugated 
secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). Ub-PEST 
(gift of Dr. Martin Rechsteiner, Department of Biochemistry, University of Utah). 
4.3.2. Cell Culture 
I used RKO colon cancer cells (gift from Dr. Mark Meuth, Institute for 
Cancer Studies, University of Sheffield, Sheffield, U. K.). RKO cells were 
maintained in DMEM (supplemented with 2 mM L-glutamine, 1 mM sodium 
pyruvate, 50 units/ml penicillin and streptomycin, and 10% (v/v) FBS) in a 
humidified incubator with 5% CO2• 
4.3.3. Immunochemical Detection of Proteins 
I removed the medium and lysed cells in 50 mM Tris, pH 7.4, 100 mM 
NaCl, 2 mM EDT A with 0.1 % SDS, 0.1 % deoxycholate, 1 x complete protease 
inhibitor mixture. Protein concentration was measured by the Bradford method. 
Equal portions of the total cell lysate from each sample (12.5 Ilg of protein) were 
fractionated by SDS-PAGE and transferred to poly(vinylidene difluoride), which 
was blocked with 50/0 (w/v) nonfat dry milk in Tris-buffered saline [20 mM 
Tris'HCl, pH 7.5, 100 mM sodium chloride, 0.1 % (v/v) Tween 20]. Proteins were 
detected immunochemically by using primary antibodies directed against Sumo-l 
(1: 1000), GRP78 (1 :250), HSP70 (1: 1000), or ubiquitin (1: 1000), followed by 
horseradish peroxidase-conjugated secondary antibodies (1 :4000). Antigen-
antibody complexes were detected with enhanced chemiluminescence reagents. 
Lastly, gels were scanned and band intensities were quantified using Kodak 1 D 
Image Analysis Software. 
4.3.4. In vitro Ubiquitin Isopeptidase Activity Assays 
I measured cellular isopeptidase enzymatic activity with ubiquitin-PEST 
(Ub-PEST), a full-length ubiquitin molecule with an 18 amino acid c-terminal 
peptide extension (total mass = 10.5 kDa). Ubiquitin isopeptidases specifically 
cleave the 18 amino acid peptide extension, releasing full-length ubiquitin (8.5 
kDa). Briefly, we lysed RKO cells in 50 ~L of 25 mM HEPES, 5 mM EDT A, 
0.1 % CHAPS,S mM A TP, pH 7.5. I adjusted the protein concentration of each 
sample to 0.3 mg/mL and incubated with 0-360 ~M PGA 1 or il12-PGJ2 for 1 
86 
hour. Treated lysates were incubated with 50 ~g/mL Ub-PEST for 45 minutes at 
25°C. Under these conditions Ub-PEST hydrolysis occurs at a linear rate. I mixed 
20 ~L samples with 20 ~L 2X Laemmli buffer, boiled briefly, and fractionated by 
SDS-PAGE. Last, isopeptidase activity was monitored by determining the extent 
of product (8.5 kDa ubiquitin) formation. 
4.3.5. UCH-L3 Activity Assay 
I measured the enzynlatic activity of ubiquitin c-terminal hydrolase-L3 
(UCH-L3) with ubiquitin-PEST (Ub-PEST) as above. Briefly, I pre-incubated 10 
nM UCH-L3 in 10 mM DTT, 0.1 mg/mL BSA, and 50 mM Tris, pH 7.4 for 15 
minutes. UCH-L3 was then incubated with either DMSO or 60 ~M il12-PGh for 
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3 hours at 4°C, followed by incubation with 50 ).lg/mL Ub-PEST for 2 through 8 
hours at 25°C. Under these conditions Ub-PEST hydrolysis occurs at a linear 
rate. I mixed 20 ).lL samples with 20 ).lL 2X Laemmli buffer, boiled briefly. and 
fractionated by SDS-PAGE. Last, isopeptidase activity was monitored by 
determining the amount of product (8.5 kDa ubiquitin) formation. 
4.3.6. Protein Degradation Assay 
I plated 1.5 x 105 RKO colon cancer cells into each well of a 12 well plate 
and incubated overnight. Each well was aspirated, washed twice with medium 
lacking methionine, and filled with 0.25 mL of media lacking methionine but 
having 200 ).lCi of 35S-methionine. Cells were incubated with 35S-methionine for 
2 hours, aspirated, washed twice with cold phosphate buffered saline (PBS), and 
incubated with 0.5 mL of media containing methionine, chloroquine (200 J.lM; to 
inhibit lysosomal degradation), and desired treatment for 2 hours. Wells were 
again aspirated and washed twice with PBS. Cells were then lysed in 50 mM Tris, 
pH 7.4, 100 mM NaCI, 2 mM EDT A, 0.1 percent SDS, 0.1 percent deoxycholate, 
and IX complete protease inhibitors. Intact protein was precipitated from the cell 
lysates with 10 percent trichloroacetic acid (TCA), incubated on ice for 30 
minutes, and subjected to centrifugation (15,000 x g, 10 minutes). TCA soluble 
peptides (supernatant) were then separated from insoluble, intact peptides (pellet) 
for analysis by scintillation. Percent soluble peptides was determined with the 
following equation: soluble counts/(soluble counts + pellet counts) X 100. 
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4.3.7. Trypan Blue Exclusion Assay 
I plated 1.5 x 105 RKO colon cancer cells into each well of a 12 well plate 
and incubated overnight. Cells were treated as indicated for 7 hours. The media 
from each well was transferred to a microcentrifuge tube, and the cells from each 
well were trypsinized, placed into the corresponding microcentrifuge tube, and 
subjected to centrifugation (450 x g, 3 minutes). The media was aspirated from 
each tube, leaving approximately 100 flL left in each tube, and 100 flL of try pan 
blue dye was added. Cells were pi petted into a hemocytometer and the percentage 
of blue-stained cells (dead cells) was determined. Approximately 400 cells were 
counted per treatment. 
4.3.8. Fluorometric Histochemistry 
I plated RKO cells on 8-well chamber slides at 2.5 x 104 cells per well in 
standard medium. Cells were incubated with DMSO, 60 flM ~ l2-PGh, or 20 flM 
MG 115 for 4 hours. Cellular lysosomes were stained with 50 nM LysoTrackerTM 
Red DND-99 and DNA was stained with 100 nM Hoechst 33342 for 1 hour. Cells 
were washed with cold STP buffer, fixed in a 10 percent formalin solution, and 
washed 2x with STP buffer. To protect from photobleaching, the cells were 
mounted in ProLong® Antifade reagent prior to fluorescence microscopy. 
4.3.9. Statistics 
We used analysis of variance (ANOV A) for statistical calculations. 
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5.1. Background: Cyclopentenone PGs in Apoptosis 
Prostaglandins [Figure 5.1] are molecules that are deri ved from the 
conversion of arachidonic acid to PGH2 by the cyclooxygenase enzymes, COX-I 
and COX-2 I, COX-l is a constitutively expressed enzyme, the function of which 
is necessary for cellular homeostasis. COX-2, however, is an inducible isoform, 
the expression of which is significantly elevated at sites of inflammation and in 
cancer I. Many of the PGs have physiological effects on smooth muscle via their 
properties as ligands for G-protein coupled receptors 2, The spontaneous, and 
albumin catalyzed, dehydrations of PGE2 and PGD2 lead to the formation of the 
cyclopentenone PGs, PGA2 and L\12-PGJ2, respectively 3.4. Cyclopentenone PGs 
do not act via G-protein coupled receptors and do not have effects on smooth 
muscle. However, these PGs have gained activity that the non-cyclopentenone 
PGs do not generally possess: relative potency with regard to induction of 
apoptosis 5. Despite many years of study, no cohesive data set has led to a 
definitive mechanism of action with regard to induction of apoptosis by 
cyclopentenone PGs [Figure 5.2]. 
Due to the apoptosis-promoting activity of the cyclopentenone PGs, there 
is a great deal of interest in finding their mechanism of action. Adding to this 
interest is the fact that they appear to cause apoptosis by a novel mechanism, 
since cell lines that have developed resistance to standard chemotherapeutics 
remain sensitive to cyclopentenone PGs 6,7, Furthermore, cyclopentenone PGs 
appear to sensitize cells to certain clinically useful chemotherapeutics, in 





























Figure 5.1. Representation of Various Prostaglandins. Shown are a representation 
of prostaglandins (PGs) that have effects on G-protein coupled receptors (left 
column). Arrows indicate spontaneous and/or albumin catalyzed dehydration that 
lead to the formation of the cyc1opentenone PGs (right column). Cyc1opentenone 
PGs are relatively more potent than their respective noncyclopentenone parent 













Figure 5.2. Previous Model for the Cellular Effects of PGs. Shown is a schematic 
representing the effects of the two major classes of PGs, smooth muscle effects 
and apoptosis. The role of various noncyclopentenone PGs as activators of G-
protein coupled receptors is well established. No coherent rationale exists 
explaining why cyclopentenone PGs cause apoptosis. 
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damaging agents are the mainstay of clinical treatment regimens. enhancing their 
activity in vivo may be useful in treating cancers that acquire resistance to DNA 
damaging agents or cancers typically not amenable by treatment with DNA 
damaging agents. 
The interest in discovering the mechanism of action for the 
cyclopentenones also stems from more practical considerations. When 
administered to whole organisms, the half-life of these compounds is relatively 
short « 1 0 minutes in vitro and in vivo) 9,10. Therefore, finding the relevant 
target(s) for these compounds may lead to the development of more specific 
compounds having more favorable pharmacological profile (i.e., greater 
specificity, bioavailability, potency, etc.). 
S.2. Previously Stated Hypotheses 
S.2.1. PPARy Activation Causes Apoptosis 
The great interest in the cyclopentenone PGs, due to the promising 
apoptotic effects seen in model cell lines, has generated several hypotheses as to 
their mechanism of action. The most prominent of these hypotheses regards the 
relationship ofPGs of the J-series, in particular IS-deoxY-812,814-PGh(lSd-
PGlz), as agonists of the peroxisome proliferator-activated receptor, isoform 
gamma (PPARy). PPARy is a nuclear hormone receptor that activates genes that 
regulate adipogenesis. lSd-PGh is the highest affinity, naturally occurring 
cellular ligand known for this receptor 11,12. It has been suggested that activation 
of PPARy is the mechanism by which 812-PGJ2 causes cell cycle arrest and 
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induces apoptosis 5,13-15, However, several problems exist with this model. ~12-
PGh is a much lower affinity ligand for PPARy, yet in it is as potent at inducing 
apoptosis as 15d-PGJ2 16,17, 15d-PGh causes apoptosis in cells that do not express 
the PPARy receptor 18, PPARy antagonists have no effect on ~12-PGh-induced 
apoptosis 19,20. Finally, synthetic PPARy agonists (e.g. thiazolidinediones), which 
have much higher affinity for PPARy than does 15d-PGJ2, are not as potent at 
inducing apoptosis as PGs of the J-series, and in fact do not cause apoptosis 
themselves unless at much higher concentrations than would be necessary to 
saturate PPARy binding 20. Interestingly, one recent study demonstrated that 
cyc1opentenone prostaglandins induced activation of PPARa and PPARo, without 
binding to these receptors, suggesting these receptors are not activated directly by 
the PGs, but instead by some unknown alternative mechanism 21, This opens up 
the possibility of alternative mechanisms for the activation of PPARy by ~12-
PGh. 
5.2.2. Heat Shock Protein Induction Causes Apoptosis 
One of the original phenotypes observed in cells treated with 
cyc1opentenone PGs was the induction of heat shock proteins (HSPs) :;2. This 
prominent phenotype has led some to hypothesize that the induction of HSPs is 
the causal factor for PG-induced apoptosis 23, Indeed, PGs of the J-series mimic 
heat shock with regard to induction of heat shock proteins and G 1 arrest; 
however, these studies never demonstrate a causal relationship between the HSPs 
and G 1 arrest. Heat shock causes the unfolding of proteins by denaturation, 
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therefore, any number of factors may be responsible for cell cycle arrest. In facL 
the role of HSPs as molecular chaperones that aid in the refolding of denatured 
proteins supports the idea that HSP induction is consequence and not a cause, 
Furthermore, one study demonstrated that HSP overexpression actually protects 
cells from PG-induced apoptosis 24, 
5.2.3. Induction of Important Regulatory Proteins Causes Apoptosis 
Many of the remaining hypotheses regarding cyclopentenone PG-induced 
G 1 arrest and apoptosis center around the observed accumulation of various 
proteins. For example, p53 has been shown to be up-regulated in a number of cell 
lines due to cyclopentenone PG treatment 25.26. Since p53 protein levels are 
regulated not by transcription but by degradation, the general assumption in these 
studies is that p53 is accumulating due to signaling events (analogous to DNA 
damage signals) thus activating it as a transcription factor. Supporting this 
evidence, p21 Waf!, a target gene of p53-mediated transcription, is often seen to be 
up-regulated at the protein level 26-28. However, no studies have demonstrated that 
the accumulated p53 is actually active as a transcription factor. In fact, as our 
work has shown, p53 in not active as a transcription factor despite its 
accumulation 29. Furthermore, the effects of cyclopentenone PG treatment (e.g. 
G 1 arrest, p21 accumulation, and apoptosis) are similar in cells that lack p53 30. 
Lastly, other than demonstrating the accumulation of these proteins, no evidence 
is provided suggesting why they are accumulating. 
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5.3. Proposed Model: Inhibition of Protein Degradation 
Causes Apoptosis 
The model proposed herein [Figure 5.3] is one in which cyclopentenone 
prostaglandins (with PGs of the J-series being relatively more potent than PGs of 
the A-series) inhibit a ubiquitin isopeptidase(s) that is essential for maintaining 
the proper intracellular balance between monoubiquitin and polyubiquitin. The 
disruption of this balance by PGs leads to an accumulation of polyubiquitin, and 
subsequent depletion in monoubiquitin [Figure 3.4], and a decrease in global 
cellular protein degradation by the proteasome pathway [Figure 4.5], similar to 
catalytic site proteasome inhibitors. If correct this model would reconcile many of 
the observations made in cells treated with cyclopentenone PGs. 
First, the inhibition of protein degradation is predicted to cause an 
accun1ulation of many normal and misfolded proteins that would normally be 
targeted for degradation. This could account for the accumulation of p53 (normal 
• .j:' ld d d 21 Wafl d ")')-'8 and mlSlO e ) an p observe by our group and others h_ - • Also, we 
speculate that protein accumulation could help explain the proposed alternate 
mechanism for PPARy activation. PPARy activation involved its 
heterodimerization with the retinoic acid X receptor, isotype alpha (RXRa) 31. 
RXRa is degraded by the proteasome pathway, therefore its accumulation may 
result in increased binding and activation of PPARy 32. 
Second, the model I propose helps reconcile all of the various 
cyclopentenone PG-induced stress responses. The accumulation of 
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Figure 5.3. The Proposed Model for Cyclopentenone PG-Induced Apoptosis. 
Shown is a schematic representing the model proposed herein for cyclopentenone 
PG-induced apoptosis. First, cyclopentenone PGs inhibit the proteasome pathway, 
via isopeptidase inhibition. Similar to the effect of catalytic-site proteasome 
inhibitors, this causes the accumulation of normal and unfolded proteins to toxic 
levels, resulting in the apparent up-regulation of specific proteins and the 
induction of the heat-shock response. This model proposes that the inability of 
cells to degrade accumulating unfolded proteins results in cytosolic and ER 
unfolded protein response (UPR) activation and apoptosis. 
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deranged/unfolded proteins triggers the heat shock response of the cytoplasm and 
the unfolded protein response (UPR) of the endoplasmic reticulum (ER). Genes 
up-regulated by these responses include the cytoplasmic HSPs. HSP70 and 
HSP90. the ER resident HSP, GRP78 (BiP), ubiquitin-B, and ubiquitin-C 33, 
Supporting that the inhibition of the ubiquitin-proteasome pathway by 
cyclopentenone PG could be cause these effects, catalytic site inhibitors of the 
proteasome cause up-regulation of the cytoplasmic and ER HSPs and ubiquitin 34, 
Last, this model would help explain why the protein synthesis inhibitor, 
cycloheximide, protects cells from cyclopentenone PG-induced apoptosis, Due to 
the mechanism of action of cycloheximide, this effect has always been correctly 
assumed to be the result of inhibiting nascent protein synthesis 35. However, some 
studies have attempted to link this phenomenon with the inhibition of the 
synthesis of a particular protein 36. The model I propose suggests a more global 
explanation in which cycloheximide simply prevents the synthesis of proteins that 
would only add to a growing pool of deranged/unfolded proteins. In this way 
cycloheximide may delay cytoplasmic ER stress cause by cyclopentenone PGs. 
Supporting this hypothesis are data presented here [Figure 4.6] demonstrating that 
cycloheximide also protects cells from the effects of catalytic site inhibitors of the 
proteasome. 
In summary, cyclopentenone PGs share in common with catalytic-site 
proteasome inhibitors the following properties: disruption of ubiquitin 
homeostasis, inhibition of protein degradation, accumulation of a number of 
proteins regulated by the proteasome pathway, up-regulation of heat shock 
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proteins, and rescue from cell death by cycloheximide co-treatment. Therefore, 
many of the observations previously made regarding the effects of 
cyclopentenones PGs can be reconciled with our model that these compounds 
inhibit the proteasome pathway via inhibition of ubiquitin isopeptidase activity 
[Figure 5.3]. 
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